DIABETES

The Journal of the American Diabetes Association

INDEX

BY SUBJECT AND AUTHOR



VOLUME 6

1957

104237

Copyright 1958, by American Diabetes Association, Inc.

MAYO CLINIC
LIBRARY

SUBJECT INDEX 1957

This index covers all reading matter in Volume 6 of DIABETES. Entries marked with an asterisk (*) indicate material which appeared in the ABSTRACTS only. The author index appears on page 15.

A

ACETALDEHYDE, and carbutamide, 28-32

ACETATE
in cholesterol of liver slices, *120
oxidation
and carbutamide, 43
and ketogenesis, *546

ACETOACETATE
in adrenalectomized rat liver slices, *120
in dehydroascorbic acid diabetes, *462
in diabetic livers, *546
oxidation, and ketogenesis, *546
reabsorption, and glucose, *109

ACETONE BODIES: *See* Ketone bodies

2-ACETYLAMINO-1, 3, 4-THIODIAZOLE - 5 - SULFONAMIDE: *See* Diamox

ACID: *See* specific acid

ACIDOSIS, DIABETIC
and acetylation of p-aminobenzoic acid, *547
and antibiotics, *456
in brittle diabetes, *465
and fatty acids
plasma content, *115
unesterified, 477
and insulin administration, 477
acetylation ratio after, *547
and insulin resistance, 407
humoral, *110-111
and renal tubule
osmotic activity, *114
reabsorption, *109
treatment, and parenteral potassium, *294

ACROMEGALY, and carbutamide, 70-71

ACTH: *See* Corticotropin

ADDISON'S DISEASE, with diabetes, 436-440

ADENOMA
adrenocortical, and tolbutamide, 78-79
beta-cell, and diabetes compensation, *112

ADRENAL CORTEX
atrophy prevention, *460
and DDD, *300
and diabetes duration, 482-483
and experimental lesions, 184-185
and familial hypertrophy, *120
and 17-hydroxycorticosteroids, *378, *461
insufficiency, and steroid therapy, *206-207
and pepsinogen excretion, 482-483
in thyroidectomized dogs, *378
tumor, 78-79
and amphenone, 331-332
and reversible diabetes, *549
and vascular changes, 182, *297, *378

ADRENAL GLAND
autopsy findings
after Addison's disease with diabetes, 438, 439
after steroid therapy, in cat, 430
tuberculous necrosis, 440
cholesterol, and ascorbic acid, *296
function, in alloxan diabetes, *113
and glucagon, 254
protein catabolic effect, 251-253
and hyperglycemia after diethyldithiocarbamate, 158
and sulfonamides, 409, 413
and sulfonylurea compounds, 41, 86

ADRENAL MEDULLA
and sulfonylureas, 86
tumor, and reversible diabetes, *549

ADRENALECTOMY
arterial glucose after, 240
cholesterol and fatty acids after, *120
and diethyldithiocarbamate effects, 156-157
glucose-6-phosphatase levels after, 153
and insulin, *296
hypoglycemia, *112
and muscle glycogen levels, *456
nitrogen and urea nitrogen excretion, 251
sulfonylurea effects after, 11-12, 53, 86 91-92
tolbutamide therapy after, 270

ADRENALIN: *See* Epinephrine

ADRENOCORTICAL STEROIDS: *See* Steroids

AGE
and angina pectoris, 159, 163
and arteriosclerotic heart disease, 164-165
and blood pressure, *114
and cholesterol transport, 181
and diabetes: *See* Diabetes mellitus, in childhood; in infant; juvenile
and fertility patterns, 401
and glucocorticoids, 170
and islet cell changes, *382
and retinopathy, *114
and vascular complications, *212
peripheral changes, 159-160

AGRANULOCYTOSIS
and carbutamide, 73, *208
and sulfonylureas, 86

ALBUMIN, serum content, and Orinase, 149

ALBUMINURIA
and diabetic
nephropathy, 161
pregnancy, 526-528
and edema, 163
and globulin levels, *547

ALCOHOL
and carbutamide, 87
metabolism after, 28-32
and fatty liver, *116-117

ALDOSTERONE, secretion
and amphenone, 330
and ACTH circulating levels, 333
after hypophysectomy, *121

ALDOSTERONISM, and diabetes, *549

ALLERGY
and carbutamide, 40-41, 45, 73, 76, 88-89, *125
and sulfonylureas, 88-89, 92, 283

ALLOXAN, DIABETES: *See* Diabetes mellitus, alloxan induced

AMERICAN DIABETES ASSOCIATION
Affiliate Associations
news, 131, 219-220, 305, 389, 472
symposium of The Clinical Society of the New York Diabetes Association, 221-289
annual banquet, 386-387
annual business meeting, 467-471
annual meetings
eighteenth, 387, 471, 556
seventeenth, 129, 214, 385-386
Banting Memorial Lecture, 215, 391-399, *539
cable address, 305
Committees, 554-556
name change to "Informational Committee on Oral Hypoglycemic Compounds," 218
Committees: reports
on Camps, 97-98
on Medical Standards, 126-129
on Employment of Diabetics, 550-554
Informational, on Oral Hypoglycemic Compounds, 290-291
on Statistics, 187-190, 442-445
correspondence, 103, 203, 371-373, 451-452, 536
council, officers and members, 126, 214, 302, 385, 467, 550
Diabetes Week, 130, 389, 472
essay contest, 130, 387-388, 472, 557
identification card, 130

International, third congress, 303, 389, 471, 557
Journal
editorials
Canadian and British Experiences with Sulfonylureas, 191-193
The Clinical Use of Tolbutamide in Diabetes Mellitus, 290-291
Idiopathic Hypoglycemosis in Children and Central Nervous System Damage, 368-369
Insulinase, 448
Mechanical Factors in Localization of Atherosclerosis, 365-367
Myocardial Metabolism in Diabetes, 95-96
Ocular Nerve Palsy in Diabetes, 535-536
The Oral Hypoglycemic Sulfonylurea Compounds, 195
The "Permeability" Hypothesis of the Action of Insulin, 446-447
The Responses of the Smaller Blood Vessels and the Serum Proteins in Pregnant Diabetic Subjects, 363-364
What the Patient Should Be Told About the Oral Hypoglycemic Compounds, 534-535
Lilly award, 218, 303-304, 386, 388-389, 472, 557
new members, 130, 218-219, 304-305, 389, 473, 558
news notes, 131, 220, 305, 390, 473, 558
obituaries, 132, 390, 474, 558
personal news, 131-132, 306, 390, 474, 558
postgraduate course, 218, 220, 302-303, 387, 474
publications
"Employment of Diabetics in the Federal Service," 306
new meal planning, 305
research fellowships, 131, 303, 389, 472
scientific program, 129, 215-218, 386, 387, 471, 556
statement on tolbutamide, 290-291
teaching kit, 306

AMINO ACIDS
blood levels, 250
and nitrogen metabolism, 323
and insulin synthesis, 225
from carboxypeptidase, 237
catabolism, after hypophysectomy, 150
and glucagon
composition, 234, 256
dosage, 250
sequence, 234-238
in lieu of food proteins, 255
oral intake, 497
and pancreatic enzymes, °381-382

AMINOBENZENE, site of action, 33

P - AMINOBENZOLSULFONAMIDISOPROPYLTHIODIAZOL
blood sugar reducing properties, 140
as insulin substitute, 260-261
mechanism of action, 263
hypoglycemic deaths, 90

p-AMINOPHENYLSULFONYL BUTYLCARBAMIDE: *See* Carbutamide

AMMONIA, excretion control, °115

AMPHENONE
and carbohydrate metabolism, 330-334
toxicity, 334

AMPUTATION, technic, °299
transmetatarsal, °464

AMYLASE, and glycogen degradation, 394

ANEMIA
carbutamide reaction, 73, 76
pernicious, and diabetes, °378

ANESTHESIA
and diabetes, °375
and tolbutamide, 9

ANEURYSMS, capillary
and Cushing's syndrome, 185
specificity, in diabetes, 183-185

ANGINA PECTORIS
age factor, 159, 163
and diabetes, 161, 346
hypertension with, 163
illness duration and, 163

ANTIBODY, and insulin
binding, 402-406
neutralizing, °205
technic, 354-357

ANTISERUM, and insulin complex, 404

AORTA
arteriosclerosis, 161
calcification in diabetes, 164
intimal sclerosis, 349
lipid concentration, °110
phospholipid, 110

ARABINOSE
insulin and tolbutamide effects after, 422-424
saponifiable lipid excretion after, °461

ARBUTIN, and insulin degradation, 25

ARCUS SENILIS, defined, 347-348

ARTERIES: *See* Blood vessels

ARTERIOLES: *See* Blood vessels

ARTERIOSCLEROSIS
See also Atherosclerosis
of aorta, 161
cardiac deaths with, 186
of coronary arteries, 161
and diabetes, 346
insulin control, °544
obliterans, 346
and diabetic foot, °541
of pancreas, °117-118
and systolic hypertension, 165

ARTOSIN, and blood sugar, 141

ARYLSULFONYLUREAS
See also Sulfonylureas
action site, 33
metabolic effects of compounds, 41-44

ASCORBIC ACID
and insulin sensitivity, °296
and ketone body metabolism, °109

ATHEROSCLEROSIS
See also Arteriosclerosis
and cerebral thrombosis after sulfonylureas, 61
cholesterol, and serum lipoproteins, 346, 348, 351-352
choline citrate, in experimental, °115
coronary, ergonovine stress test, °383
diabetic, °549
and nondiabetic, 183
localization, mechanical factors, 365-367
plasma content, °122, 181

AZOTEMIA, in Kimmelstiel-Wilson syndrome, °548

B

BANTING MEMORIAL
lecture, 215, 391-405
meeting of British Diabetic Association, °539

BARBITURATES, and carbutamide, 31

BASANT KUSUMAKER RASA, °465

BICARBONATE, reabsorption and potassium, °111-112

2, 2-BIS-1, 1-DICHLOROETHANE, in diabetes, °300

BIS-DISULFIDE, insulin degradation inhibition, 25

BLOOD
a-ketoglutarate levels
in ambulatory diabetics, °299-300
after insulin, and after Orinase, 42
sulfonyl-hydrate A-V differences, °540
after carbutamide, 12-16, 151
and alcohol metabolism, 28-32
clotting
and alimentary fat, °211
prothrombin time, 148-149, 151
thrombelastogram amplitude, 435
and glucagon
amino acid levels, 250
eosinophiles, 46-53
pepsinogen levels, °541
phosphate-glucose relation, 254
glucose. *See* Blood sugar
glycolysis inhibition, 176-178
ketone bodies, in juvenile diabetics, 66
lactate
and arylsulfonylureas, 44
and hydrocortisone, °206-207
after Orinase, 148-149
and insulin, 44
pyruvate levels, 28-32, 44
in ambulatory diabetics, °299-300
and hydrocortisone, °206-207
sugar. *See* Blood sugar
after sulfonamides. *See* Sulfonamides
urea nitrogen, after growth hormone in pituitary dwarfism, 518

BLOOD FLOW. *See* Circulation

BLOOD PRESSURE
and age, °114
and arterial lesions, 185
capillary, and retinal and renal lesions, 185-186
in diabetic pregnancy, 311, 526
and epinephrine versus glucagon, 256
and retinopathy, °114

and sex, 346-347, 351-352
and systolic hypertension, 164-165

BLOOD SUGAR
See also Hyperglycemia; Hypoglycemia
and ACTH in insulin resistance, °378
and adrenal
insufficiency, 440
oxygenated steroids, °543
and alcohol metabolism, 28-32
and Artosin, 141
and arylsulfonylureas, 41-44
after ascorbic acid pretreatment, °296
and beta-cell stimulation, 45
and body functions, °459
and carbutamide: *See* Carbutamide
after coma induction in schizophrenia, 405
correlation
with glucose-6-phosphatase level, 153
with urine sugar, °463
after cortisone-glucose, 169, 174-175
in diabetic pregnancy: *See* Pregnancy
after diethydithiocarbamate, 154-158
and dihydroergotamine, 288, °466
estimation, methods for, °380, °462, °545, °549
and glucagon
arteriovenous differences, 240-245
in force-fed rats, 249-251
dosage and effects, 252-254
metabolism, 57
regulation, °209
and glucose
enzyme test strips, °380
oral, 169
and growth hormone, 288
in hypophysectomized patient with diabetes mellitus, 519
in pituitary dwarfism, 518
and insulin: *See* Insulin
after liver removal, 240, 243, 277
in obese-hyperglycemic mice, °466
and oral substitutes for insulin, 259-261
and Orinase: *See* Orinase
after pancreas removal, 45, 411
in pig, newborn, °459
and placenta permeability, °458
postprandial, °462-463, 524
after prednisolone-glucose, 169, 174
and diabetic heredity, 172
after prednisone-glucose, 169, 174
in pregnancy: *See* Pregnancy
and senile confusion, °379
specimen preservation, 176-178
and sulfonamides: *See* Sulfonamides
and sulfonylureas: *See* Sulfonylureas
and Synthalin, 138-139
and thiodiazoles, 409-415
and tolbutamide: *See* Tolbutamides
and unesterified fatty acids, 478

BLOOD VESSELS
See also specific condition or disease
and adrenocortical function, °297
calcification, 3, 183, 349-352
classification of grades, 350
changes in diabetes
and complications, 159-166
and duration of illness, 161-162
grading, 309-315, 322
of smaller, during pregnancy, 309-322
disease: panel discussion, 180-186
lesions, 180-186
and heredity, 181
ocular, °465
and Orinase, 37
peripheral disease, °212
polarization of beta cell granules, 232
postsulfonamide liberation of insulin, 409
retinal
and adrenal cortex, °378
and retinopathy, °114

BODY WEIGHT: *See* Obesity; Weight

BOOK NOTICE, Treatment of Kidney Diseases and High Blood Pressure, by Frederick M. Allen, 305

BOOK REVIEWS
ABC for Diabetics, by F. Bertram, 293
Actual Problems in Diabetes, edited by E. Bertram and J. Kuntze, 538
The Adrenal Cortex, by I. Chester Jones, 453
Clinical Physiology, edited by Arthur Grollman, 538
The Complete Book of Low Calorie Cooking, by Leonard Louis Levinson, 105-106
Coronary Heart Disease in Young Adults, by Menard M. Gertler, et al.
Cowdry's Problems of Ageing-Biological and Medical Aspects, edited by A. I. Lansing, 103-104
Diabetes Mellitus, by B. Hejda and J. Syllaba, 454
Diabetes Mellitus with Emphasis on Children and Young Adults, by T. S. Danowski, 454
Diabetes Mellitus: Handbook for Physicians, by Howard F. Root, and Priscilla White, 373-374
Diagnosis and Treatment of Vascular Disorders, edited by Saul S. Samuels, 104
Essays in Biochemistry, edited by Samuel Graff, 293
Hormones and the Aging Process, edited by Earl T. Engle and Gregory Pincus, 374
The Human Body, by C. H. Best and N. B. Taylor, 452
Human Physiology, edited by Bernardo A. Houssay, et al.
Hypothalamic-Hypophysial Interrelationships, edited by William S. Fields, et al.
The Inquisitive Physician, by Francis M. Rackemann, 204
Noradrenaline, by U. S. von Euler, 454
Perspectives in Physiology, edited by Ilza Veith, 105
Recent Progress in Hormone Research, edited by Gregory Pincus, 453
Reduce and Stay Reduced, by Norman Jolliffe, 537-538

BRAIN
acetylcholine content, in insulin hypoglycemia, °109
and carbohydrate metabolism, 455
carbutamide effects, 76
glucose and galactose transport into and insulin, °119
thrombosis, and sulfonylureas, 61

BRISBANE, John, 196-202

BRITTLE DIABETES: *See* Diabetes mellitus, brittle

BROMSULPHALEIN, clearance
and carbutamide, 61, 147
and Orinase, 148-149

BRUNNER, Johann Conrad, 537

BUTYLAMINOBENZENESULFONYL-UREA: *See* Carbutamide

BZ-55: *See* Carbutamide

C

CALCIUM
retention, and growth hormone, 515
vascular deposits: *See* Blood vessels, calcification

CAMPS FOR DIABETIC CHILDREN, 97-98
medical standards, 126-129

CANCER
and amphenone, 331-332
and carbohydrate metabolism, °210, °379
and terminal amelioration of diabetes, °460-461

CAPILLARIES: *See* Blood vessels

CARBOHYDRATE
and heart, in diabetic and nondiabetic, 425
intake, and blood glucose, 61
metabolism, °122
and alpha cell cytotoxins, 135-143
and amphenone, 330-334
in cancer, °210, °379
and carbutamide, °205, °459-460, °539
in alcohol metabolism, 28-32
in Cushing's syndrome, °543
in depancreatectomized dogs, 147
and Diamox, °297-298
endocrine effects, °205
and glomerular changes, °544
of Mycobacteria aviary and paratuberculosis, °109
and pancreatic islet changes, 135-143, °207-208
and postprandial blood content, 524
and potency of glucocorticoids, 173
in pregnancy, 324-329, °462-463, 524
in rat liver slices, °107
in schizophrenia, °455
and spontaneous hypoglycemia, °301
nutrition, and vitamin B complex, 279
tolerance
and adrenal steroids, °543
and hydrocortisone secretion, °206-207

2-CARBOXYAMINOPROPIONYLPHENYL, inhibition of insulin degradation, 25
absorption and excretion, individual differences, 88
after adrenalectomy, 19
and agranulocytosis, 73, °208
and alcohol, 87

metabolism, 28-32
allergic reactions, 40-41, 45, 73, 76, 88-89, °125
anterior hypophysis after, °460
in atrophy prevention, °460
and barbiturates, 31
and bile duct obstruction, 43
and blood sugar, 2-6, 10-16, 21-24, 28-32, 45, 60, 68, 70-71, 74-75, 77, 91, 140-141, 147, 152, °294, °295-296, °464
bone marrow depression, 73
and bromsulphalein clearance, 61, 147
and carbohydrate metabolism, °205, °459-460, °539
and cerebrovascular accident, 76
and cholesterol serum levels, °297
and cirrhosis, 44-45, 69
and convulsions, 2-7
and crystalluria, 2-7, 73
and cytochrome oxidation, 30-31
in depancreatectomized dogs, °123, 146-149, 151-153, 288-289, °294
and dermatitis, exfoliative, 73, 84
in diabetes
and acromegaly, 70-71
ambulatory patients, °464
degree and period of treatment, 75-77
for elderly, °108-109, °112, °117, °121
and thyroid function, 80-82
and insulin requirements, °123, °125, °152, °208, °212, 278, 283. °464
juvenile, 66-67, 86, °108, °109, °117, °209, °539
obese, °108, °112
stable, middle-aged, °300
uncontrolled, °115
unstable, 46-48, 53, °124

CARBUTAMIDE
and diarrhea, 76
dosage
and body weight, 32
for hypoglycemia and for insulin degradation, 25-26
individual and species differences, 32, 90
and insulin resistance, 285
suggested, °547
and toxicity, 43, 88
and edema, 73
pulmonary, 70
and eosinophilia, 69-70, 73
and epinephrine, 19
in experimental animals, 21-23
toxicological studies, 2-7
in Germany, 40-41
and in United States, 88-89, 283
and glucose
hepatic output, 53
tolerance, 66-67, 86
and glucose-6-phosphatase activity, 22-24
and glycogen deposition, 19, 30
and glycogenolysis by liver, 31
heart lesions after, 14-16, 69, 73
hypoglycemic action, 25, 76, 85, 90, °109, °210
and of 2254 RP, 409
in hypophysectomized, 19
inhibition of insulinase, 16-18, 271
and insulin, 12-16
action potentiation, 86
degradation rates, 25, 54-59
after pancreas removal, 45, 147
sensitivity, 19
and tolbutamide replacement, °547
tolerance curve, °123
withdrawal, °208
intrapancreatic infusions, 60
and jaundice, 43-45, 73, 76, 85
in ketoacidosis, after hyperketonemia, 43
liver
fatty degeneration, °460
glycogen, 19
injury, 44-45, 288-289
maintenance treatment, continuous, not intermittent, °208
mechanism or mode of action, 41, 263-264, °295-296, °547
metabolic effects, 41-43
and glucagon interrelations, 54-59
and pancreas, 12-16, 32
islets of Langerhans, 21-23
cells, 45, °459
and plasma 17-hydroxycorticosterone level, °464
and residual reducing substances of gut, 21-22
responses, 84
tests, and treatment results, 74-77
sensitivity
giant cells, 69-70
method of testing, °210
and side reactions, 72-73
sudden death, autopsy findings, 67-70, 73
and thrombocytopenia, 73, °208
and thyroid, 6-7, 23, 80-82, °108-109, °460
and thyroxin deficiency, °460
toxicity, 2-7, 40, 43, 67-70, 88, 151-153, 286-287, °547

CARDIOVASCULAR DISEASES: *See* Heart, diseases

CENTRAL NERVOUS SYSTEM, and hypoglycemic sulfonamides, 368-369, 409

CHARCOT JOINTS, °108

CHLORPROMAZINE
and pituitary ACTH secretion, °377-378
in schizophrenia, °455

CHOLESTEROL
adrenal, after ascorbic acid pretreatment, °296
dietary
in hepatic reticuloendothelial cell, °111
long term, in dogs, °465-466
excretion
intestinal, in nephrotic rats, °108
after pectin and protopectin, °461
and fat absorption, °115-116
and ketogenesis, °546
perfusate, of livers, °108, °112
removal, °378
recovery of exogenous, °461
serum
and blood pressure, 346-347, 351-352
and carbutamide, °297
and diabetic retinopathy, °548
lipoprotein fractions, 342-352
synthesis, in diabetes mechanism, °546
transport, changes with age, 181
and vascular calcification, 3, 349-352

CHROMATOGRAPHY
in diabetic pregnancy, 526
of guinea-pig native insulin, °542

CIRCULATION
coronary, and oxygen consumpton, °106
hepatic vein, in glucose output measurement, 20
pancreatic
and blood sugar after liver removal, 277
and sulfonylureas, 60
venous, return of unphosphorylated glucose, 38

CIRRHOSIS, and carbutamide, 44-45, 69

CITRIC ACID, and zinc-insulin complexes, 339-340

CLINISTIX, °381, 426, °461, °544-545

CLINITEST, 426

COBALT
and α-cells, 136-137
and hyperglycemia, 228

COMA
diabetic, °298
acute pancreatitis, °466
and Clinistix, °461
fluid balance and electrolyte problems, °213
plasma acetone concentration, °211
and renal failure, °296-297
rules for insulin administration, °295
in sixty-seven day old infant, °458
unesterified fatty acids during insulin therapy, 477
insulin
in driver, °546
in schizophrenia, 405
and Orinase, °461

CONVULSIONS
after carbutamide, 2
delayed, in adrenalectomized mice, °121
hypoglycemic
and insulin, 278
after sulfonamides, 413

CORTICOTROPIN
and aldosterone secretion, 333
and amphenone, 332
and capillary aneurysms, 182
degradation by rat liver homogenates, 58
and glucagon secretion, 256-257
and hypoglycemia, °206-207
and insulin resistance, °114, °378-379
and intermedin, heptapeptide sequence, 238
and pantothenic acid deficiency, °296
pituitary secretion, °377-378
and tolbutamide effects, 281

CORTISONE
adrenal insufficiency after, 278
and capillary
aneurysms, 182
lesions, 184

and degranulation in islets of Langerhans, 232
diabetogenic potency, 432
and ductular hyperplasia, °294
effects on lipid components, °110
experimental lesions with, 184-185
and glucose tolerance, 168-173, 406, 407
and glycosuria, 53
in cats, 430
and growth hormone responses, 518-519
and insulin requirements after Addison's disease, 440
and insulin sensitivity, °549
phospholipid turnover after, °110
and somatotrophin, °549
and sulfonylurea effects, 53
and thrombophilic patterns, 435

CRANIOPHARYNGIOMA, and growth hormone responses, 516-518, 520-521

CUSHING'S SYNDROME
and capillary aneurysms, 185
and carbohydrate
metabolism, °543
tolerance, °206-207
glucose
and Orinase, 281
peripheral uptake, °458
and tolbutamide therapy, 78-79

CYSTEINE, and insulin
synthesis, 225
zinc complexes, 339-340

CYSTINE, and insulin, 23, 225

CYSTS
in infant ovaries, °455
pseudopancreatic, °539

D

DDD: *See* 2, 2-Bis-1, 1-dichloroethane

D 860: *See* Artosin; Orinase; Rastinon

DECAMETHYLENDIGUANIDIN
See also Synthalin
and alpha cells, 137-138

DEHYDROASCORBIC ACID, diabetogenic effect, °116, °462

DELATUTIN, 526

DELESTROGEN, 526

DERMATITIS, and carbutamide, 73, 84

11 - DESOXY - 17 - HYDROXYCORTICOSTERONE, secretion in hypophysectomized dog, °121

DESOXYRIBONUCLEIC ACID, in metabolic experiments, °379

DEXTROTEST, °462, °549

DIABETES MELLITUS
and acromegaly, 70-71
and Addison's disease, concomitance, 436-440
alloxan-induced
acids of tricarboxylic acid cycle, °111
adrenal function, °113
alpha cell function, °295
and carbutamide, 22-24, 45
in absence of β-cells, 41
fluorescent reactions in islets, 357
glucose catabolism, °108
glucose-6-phosphatase activity, 22-24
and intraocular vascular system, °543
and IPTD, 140
liver responses, 24, 91
myocardial metabolism, 95-96
and Orinase, 141
versus carbutamide, 89
succinic and malic acids after fructose feeding, °107-108
and sulfonamides, 140, 408-412
and sulfonylureas, 7-12, 267
and 2259 RP, 413
amputation for gangrene, °299, °464
and anesthesia, °375
and arylsulfonylurea compounds, 41-53
atonic neurogenic bladder, 455
autopsy findings, 67-70, °384
and β cells
adenoma, °112
as causative factor, 225
hydropic degeneration, 431
brittle, °106-107, °457, °465
capillary aneurysm, specificity, 183-184
Charcot joints, °108
in childhood, °121, °383
camps, 97-98, 126-129
central nervous system damage, 368-369
development after, °298-299
and education, °382
hypoglycemosis, idiopathic, 368-369
and retinitis, °543
vascular complications, 297
cholecystectomy, °455
and collagen disease, coexisting, °548
coma: *See* Coma, diabetic
complications, 159-166, °212, °381-382, °461-462
vascular: *See* blood vessels; specific conditions
vitamin excretion, 510-512
concepts of, °121-122
control: *See* specific
and diastolic hypertension, °213
and driving, °377
employment
in Federal Service, 306
in major industry, 550-554
in eskimos, °549
etiology, 77-79, 225, 257
familial hypertrophy of pineal body, °120
glomerular lesions, °544
and glucocorticoids
excretion in retinopathy, 182
heredity factors, 168-173
history, °541, °547
hyaline vascular changes and DDD, °300
and hypercholesterolemia, °466
and hyperlipemia, °466
hyperpolysaccharidemia and DDD, °300
and hyperthyroidism, amphenone effects, 333
and hypophysectomy: *See* Hypophysectomy
identification card, 130
incidence, 160, °213
in infant
one-year-old, °381
sixty-seven-day-old, °457
instruction of patients, °464, 534-535
and insulin: *See* Insulin
insulin resistant, and ACTH, °378-379
intercurrent illness, °548
juvenile
adrenocortical activity, 482-483
and carbutamide, 66-67, 86, °108, °109, °117, °209, °539
environmental and personality problems, °465
free diets in treatment, °296
glucose tolerance, 65-67
insulin potentiation, defined, 85-86
and sulfonylurea therapy, 65-67, 267
urinary pepsinogen excretion, 480-483
and vascular complications, 159, °297
labile °457
and sulfonylureas, 61, 286
and tolbutamide, 77
laboratory aids, °457, °540
latent, °461-462
lipoplethoric, and Orinase, 77
low salt syndrome, °539
manifestations, °299
and atherosclerosis, °549
and recognition, °383
and 2259 RP, 413
metabolic defects
myocardial, 95-96
unesterified fatty acids in evaluation, 478
and vascular lesions, 180
Morocco, new nontoxic drug, °463
Nadisan-resistant, °207
nephropathy, 165, 185
neuropathy, 185, °209
nonketonuric, 65
obese or overweight, 44, °108, °211
and Orinase: *See* Orinase
and pancreatitis, °300-301, °466
penicillin usage, °295
and pernicious anemia, °378
pituitary, 431
necrosis, °295
and polyneuritis, °544, °549
"prediabetes" syndrome, °460
and pregnancy: *See* Pregnancy
and Rastinon, °458
and renal function, °457, 459
retinopathy, °114, °115, 185, °209, °210, 418-421
reversible, °549
riboflavin metabolism, 510-511
secondary to pancreatectomy, 78-79
serum lipoprotein, and cholesterol determinations, 342-352
Sorbitol as a sweetening agent, °122, °299
stable, °457
and arylsulfonylureas, 61
and carbutamide, °300
comparison with brittle, °106-107
fluid intake, 47-48
glucagon responses, 46-49
glucose metabolism, 286
and tolbutamide, 77
statistics
age, 189-190, 444
disability allowances, 190, 444-445
mortality
Canada, 187, 188, 442
England and Wales, 187, 188, 442

United States, 187-189, 442-445
by cardiac deaths, 189
by geographic region, 188, 443-444
life insurance policy holders, 188, 442
race, 190, 444-445
sex, 190, 444-445
steroid
in cat, 428-432
after prednisolone, 79
and surgery, management, °380
survey, in West Cornwall, °375
tests, °210, 359-361, °462, °463, °549
therapeutic agents: *See* specific
thrombophilic findings, 435
treatment for, °205
attempts to simplify, °208
with pterocarpus marsupium, °465
and tuberculosis, coexistence, °539-540
uncontrolled, °115
unstable
and carbutamide, 46-48, 53, °124
fluid intake, 50, 52
glucagon responses, 50-53, 254
and sulfonylurea compounds, 64-66, 267
urinary tract infections with, °301
and viral hepatitis, °210
vitamin B, urinary excretion, 508-512
Week, 130, 389, 472

DIAMOX
and carbohydrate metabolism, °297-298
in diabetic pregnancy, 526
and inhibition of insulin degradation, 25

DIET
amino acid additions, and pancreatic enzymes, °381-382
and blood sugar levels, 46-53
and cholesterol excretion, °461
in diabetes control, 66, °301, °460 °542, °543
and essential fatty acids, 362
and overweight, °110, °211
in pregnancy, 525-526

DIETHYLDITHIOCARBAMATE, alpha cell responses, 134-136, 154-158

DIHYDROCHOLESTEROL, absorption by rat's intestine, °112-113

DIHYDROERGOTAMINE and glucagon action, 288, °466

DIHYDROXYACETONE, differential permeability of rabbit placenta, °458

DIHYDROXYPHENYLALANINE, and inhibition of insulin degradation, 25

DIMETHYLCARBAMYL, inhibition of insulin degradation, 25

DITHIOURACIL, and inhibition of insulin degradation, 25

DIURETICS, in diabetic pregnancy, 526, 528

DWARFISM, hypopituitary, and responses to growth hormone, 516-518, 520-521

E

EDEMA
and albuminuria, 163
after carbutamide, 70, 73
in diabetic pregnancy, 315-316
and insulin therapy, °375
in Kimmelstiel-Wilson syndrome, °548

ENDARTERITIS, in diabetic mothers, °540

ENDOCRINE GLANDS
hyperfunction, and hypofunction, °549
and late diabetic lesions, °384
and sulfonamides, hypoglycemic action, 409

ENZYMES
adaptation, 167
and kinetic responses, 186
defect, in galactosemia, °539
pancreatic and amino acid, °381-382
tests, °206, °210, °213, °297, °298, 358-361, °378

EPINEPHRINES
action of, and adrenal steroids, °463
hyperglycemic response, 18
in obese-hyperglycemic mice, °466
and sulfonylureas, 19, 41, 91, 275
and hypoglycemic action of sulfonamides, 409
and liver
phosphorylase, °120, °124
response of slices, 16-18, 31, 91
and Orinase, 16-18, 32, 37
and phospholipid turnover, °110
and unesterified fatty acid concentration, 478
urinary excretion, after hypophysectomy, °116

ESKIMOS, diabetes in, °549

ESOPHAGUS, autopsy findings, sudden death, during carbutamide therapy, 69

ESTRADIOL, and growth hormone in pituitary dwarfism, 518

6 - ETHOXYBENZOTHIAZOLESULFONAMIDE, and insulin degradation, 25

EUGENIA JAMBOLANA SEED, antidiabetic effect, °465

EYES
See also Retina; Retinitis; Retinopathy
cataracts, °212
in grading of retinopathy, 161
diabetic changes, °118, 160-161, °209, °378, °465, 485-486, 527, °543
glaucoma, °212
hemorrhagic, 161
nerve
palsy, 535-536
paresis, °378

F

FAT
autopsy findings after steroids in cats, 430
balance, and impairment of triglyceride absorption, °460
carcass content, in obesity definition, °110
in diabetic acidosis and starvation, °115
dietary, and insulin reactions, °542
melting point and utilization, °460
metabolism, °205
perivasculitis, after injection of insulin, °545
utilization and pancreatic juice, °460

FATTY ACIDS
acetate, in liver slices, °120
essential, 362
metabolism, nonesterified, 475-478
transport, 478

FERTILITY
patterns by age and size of families, 401
and pregnancy incidence in diabetic, 523-524

FETUS
in diabetic pregnancy, 326-329, °541
survival and prematurity introduction, 524-525

FLOUNDERS, insulin and zinc, °212

FLUKES, insulin and zinc, °212

FLUOROHYDROCORTISONE
diabetogenic action in cats, 428-432
hyperglycemic effects, 170

FOLIN-WU test, °462

FOOD
consumption
in alloxan diabetes, 9
and carbutamide toxicity, 15
and glucagon dosage, 249
and glucose tolerance, °375

FOOT
care of gangrenous, °299, °464
Charcot joints, °108
diabetic
and arteriosclerosis obliterans, °541
lesions, °296, °298, °301, °379
and peripheral arterial insufficiency, 159-163

FRUCTOSE
conversion to glucose, 33, 267
and diabetes mellitus, °546
differential permeability of rabbit placenta, °458
idiosyncrasy to, °206
and ketosis, in alloxan diabetes, °107-108
metabolism, in presence of insulin, °118
thymol-hydrochloric acid reagent for determination of, °213
utilization of intravenous invert sugar, °119

FRUCTOSURIA, family history of diabetes, °461

G

GALACTOSE
cardiac muscle entry, and growth hormone, °457
conversion to glucose, after arylsulfonylureas, 33
differential permeability of rabbit placenta, °458

and fecal excretion of saponifiable lipids, °461
metabolism by isolated rat diaphragm, °118-119
transport into cells of muscle and brain, °119

GALACTOSEMIA, enzyme defect, °539

GALL BLADDER, disease, and diabetes, °299

GANGRENE
amputation technic, °299
infective, in diabetic patients, °464

GASTROINTESTINAL TRACT
absorption of dihydrocholesterol and soya sterols, in rat, °112-113
carbutamide effects, 2-7, 21-23
cholesterol and lipid excretion in nephrotic rats, °108
disturbances, and glucagon dosage, 248-249
glucose absorption from and irradiation, °109-110

GEYELIN, Henry Rawle, 291-293

GLAUCOMA, and diabetes mellitus, °212
hemorrhagic, 161

GLOMERULOSCLEROSIS, 183-184
diabetic, 161, °294
lesions, 488-495
types and sites, 490-495, °544
intercapillary, 161, 163, °546
nephrotic, in Kimmelstiel-Wilson syndrome, °548

GLUCAGON
acinar-cell granulation, 254
amino acid
blood levels, 250
composition, 256
sequence, 234-238
and carbutamide, 45-59
cell sources, 229-332
clinical usefulness, °125
and degranulation reversibility, 254
and dihydroergotamine, °466
dosage, pathologic effects, 248-254
and epinephrine, 256
function, 240-245
relationship of timing to, 240-243
and glucose
and unesterified fatty acids, 477-478
utilization, °120
glycogenolytic effect, 91
hydrolytic agents, 237
hyperglycemic response
in obese-hyperglycemic mice, °466
and sulfonamide compounds, 410
hypotensive reaction following, °457
isolation and crystallization of, °124
and liver
glycogen, 255, 257
phosphorylase, °120, °124
and poisons, 138-139
slices, 17-18, 91
and pepsinogen concentration, °540-541
peptide numbers, 237
peripheral action, 253
and phosphate-glucose relation, 254
physiologic role for, 239-245
synergist to insulin function, 252-253, 257
and protein metabolism, 254
and regulation of blood sugar, °209
secretion
factors for, 256
and growth hormone, 256-257, °466
and Prolactin, °111
site of origin, 256-257
and sulfonylureas, 19, 41, 54-59, 91, 275, °540
and Synthalin, 138-139

GLUCOCORTICOIDS
see also specific
and hydrocortisone, °206-207
hyperglycemic responses, and heredity, 168-173

GLUCOSE
absorption
arteriovenous difference, 240-245
by intact rat, °298
intestinal, °455
and obesity, three forms, °117
and x-irradiation, °109-110
blood levels: *See* Blood sugar
in dehydroascorbic acid diabetes, °462
in diabetic coma and unesterified fatty acids, 477
content of rat diaphragm
and glucosamine, °118
and insulin, °119
conversion
of fructose to, 33, 267
glycogen to, 17-18
in Cushing's syndrome
and Orinase, 281
peripheral uptake, °458
and fatty livers, °466
ingestion, 240-245
and insulin functioning activity, 245
metabolism, 286
Embden-Meyerhof pathway, °108
in extremities, 34
in liver, °120
and Orinase, 38-39
by peripheral tissue, 34, 38-39, °120
and genesis of diabetes, 250-253
in pregnancy, °375-376
and previous diet, °125
and sulfonamides, 412
and sulfonylureas, 33, 34, 89, 267, 286
and tolbutamide, 282
output
and carbutamide, 20, 53
and glucagon dosage, 251
and glucose-1-phosphate, 17
and glucose-6-phosphatase levels, 26-27
by liver, 16-18, 91, 271-272
measurement, and hepatic vein flow, 20
oxidation in virus-infected mice, °383-384
and placenta permeability, °458
and reabsorptive rates of acetoacetate, °109
renal threshold for diabetes mellitus, °463
in diabetic pregnancy, °382
sensitivity to in islets of Langerhans, 339-340
tests, 168-173, °208, °210, °381, 426-427, °461, °544-545
tolerance, 65-67
and carbutamide, °460
and cortisone, 168-173
and hyperthyroidism, °549
modification by glucocorticoids, 168-173
and obesity, °375, 477
in pregnancy, 324-329
responses of identical twins, 172-173
secondary hypoglycemia during, °458
after steroid treatment in cats, 430-431
tests, 168-173, °208, 406, 407, °463, °539, °540
in pregnancy, °462-463, 524, 531-532
transport, and insulin, °119
uptake
after carbutamide, 41
after growth hormone, °457
and insulin concentration, 27
urinary excretion
after amphenone, 330-334
and dietary intake, 8-9
urine content, °463
glucose oxidase preparations, °114, °297, 426-427

GLUCOSE-6-PHOSPHATASE
activity, 16, °462
and blood sugar levels, 153
and carbutamide, 22-24
after tolbutamide, 272
of liver, °211
inhibition in slices, 31, 273
and insulin, 175
and sustained glucose production, 26
and sulfonylureas, 91, 275

GLUTATHIONE, and zinc-insulin complexes, 339-340

GLYCOGEN
concentration, after carbutamide, 13-16
content of rat liver, and sulfonamides, °459
degradation, by β-amylase, 394-395
depletion, and Synthalin, 138
and insulin, °380
deposition, 30-31
liver
conversion to glucose, 17-18
species difference, 20
after sulfonylureas, 31, 278
metabolism, 391-399
molecular weights by different methods, 397-399
muscle
and adrenal medulla, °456
breakdown to lactate or pyruvate, 256
and carbohydrate, 425
after sulfonylureas, 31, 278
regeneration, 393-394
and storage function, 399
structure, 392
synthesis, 399
and enzyme-catalyzed reactions, 393

GLYCOSURIA
and amphenone, 333
and carbutamide, 77
in diabetes with acromegaly, 70-72
patterns of responses, 84
cortisone-induced, and sulfonylurea effects, 53
and diabetes, 8, 61, 86

enzymatic tests, °206, °213, °297, °298, °378
and copper reduction method, 359-361
and fat-free diet, °301
and hydrocortisone, 430
and IPTD, 140
after prednisolone therapy, and Orinase, 281
during pregnancy and perinatal mortality, °462-463
and steroids, in cats, 428-432
and sulfonamide therapy, 414

GONADECTOMY, and hypoglycemic sulfonamides, 409

GOWERS' LOCAL PANATROPHY, diagnosis, °545

GROWTH HORMONE
blood sugar after, and dihydroergotamine, 288
and craniopharyngioma, 516-518, 520-521
and galactose entry into cardiac muscle after insulin, °457
and glucagon secretion, 256-257, °466
and glucose-6-phosphatase activity, °211
glucosuria and postprandial hyperglycemia after, 515-521
and heart, glucose uptake, °457
and hydropic degeneration of β cells, 431
hyperglycemic effect without anabolic, 515-521
in hypopituitary dwarfism, 516
and diabetes, 517-521
and nitrogen metabolism, 150
and plasma insulin, °298

H

HARRIS, Seale, 449-451

HEART
See also Myocardium
arteriosclerosis, 159, 161-165
deaths with, and dietary fat, 186
in Kimmelstiel-Wilson syndrome, °548
carbutamide effects, 14-16, 69, 73
and diabetes, 159, 161-165, °212, 346-352
incidence, and deaths, 189
metabolic defects, 95-96
diseases: *See* specific
failure, °548
in hemochromatosis, °113
glycogen, 14-16
and carbohydrate, 425
and growth hormone, °456-457
oxygen consumption and blood flow, °106

HEPARIN
and lipoprotein spectrum, °122
plasma and pancreatic lipase clearance after, °379

HEPATECTOMY
and blood glucose, 240, 243, 277
and hypoglycemic response, 267
to tolbutamide, 270

HEREDITY
of diabetes, °298-299
and pregnancy, 326-327
and vascular lesions, 181
and glucocorticoid responses, 168-173

HGF: *See* Glucagon

HORMONES
See also specific
antidiabetogenic, production by islet tissue, 223-224
therapy in diabetic pregnancy, 526, 530, 532

HOUSSAY SYNDROME, 540

HYDROCORTISONE
diabetogenic action in cats, 428-432
and gluconeogenesis from protein, °206-207
and glucose tolerance, 170
and glycosuria, 430
secretion in Cushing's syndrome, °206-207

17-HYDROXYCORTICOSTEROIDS
in diabetic pregnancy, 531
metabolism in thyroidectomized dogs, °378
urinary excretion
after amphenone, 330-334
in hypophysectomized diabetic, 33
and aldosterone secretion, °121
and carbutamide, °463-464

HYDROXYINDOLEACETIC ACID, and insulin, 25

5-HYDROXYTRYPTAMINE. *See* Serotonin

HYPERADRENALINEMIA, 42

HYPERCHOLESTEREMIAS, °466

HYPERGLYCEMIA
See also Blood sugar
and α-cell cytotoxins, 135-143
and amphenone, 333
and arylsulfonylureas, 61
and carbutamide, 77
after cobalt administration, 228
after cortisone
and somatotrophin, °549
and sulfonylureas, 53
dehydroascorbic acid induced, °116
and diethyldithiocarbamate, 154-158
and fat-free diet, °301
fluorohydrocortisone-induced in cats, 428-432
and glucagon dosage, 251, 253-254
and IPTD, 140
and obesity, °117, 256
and Orinase, 8
after pancreatectomy, 37
after prednisolone, 281
and perinatal mortality, °462-463

HYPERGLYCEMIC - GLYCOGENOLYTIC-FACTOR: *See* Glucagon

HYPERINSULINISM: *See* Hypoglycemia

HYPERKETONEMIA, and sulfonamides, 43

HYPERLIPEMIA, 466

HYPERPOLYSACCHARIDEMIA, and DDD, °300

HYPERTENSION
and angina pectoris, 163
and benign nephrosclerosis, 183
in diabetes, °212, °213
and arteriosclerosis, 164-165
cholesterol and serum lipid fractions, 345-347, 352
pregnancy, 526-527
glomerular lesions, °544
in Kimmelstiel-Wilson syndrome, °548
and retinal hemorrhages, 185

HYPERTHYROIDISM
amphenone effects, 333
glucose tolerance, °549

HYPOGLYCEMIA
See also Blood sugar
acetylcholine content of brain during, °109
after adrenalectomy, 53, °112
agents for: *See* specific
and alpha cell cytotoxins, 135-143
causes, °545
and central nervous system damage, 368-369
and diethyldithiocarbamate, 154-158
and disulfide compound, 25
and glucagon secretion, 256-257
and hydrocortisone, °206-207
insulin-induced: *See* Insulin
and IPTD, 90
nocturnal symptoms, 61
and nonpancreatic tumors, °122-123
response anticipation, °301
spontaneous in childhood, °301
and sudden death, 70
and 2254 RP, 409

HYPOPHYSECTOMY
and adrenaline excretion, °116
and aldosterone secretion, °121
aminobenzene responses, 33, 150
and carbutamide, 19
and corticosterone secretion, °121
and hyperglycemic effects
of cortisone, °549
growth hormone, 517-521
of tolbutamide, 270
and muscle glycogen, °456
and nitrogen balance, 150
and sulfonylureas, 10-11, 86, 91-92
and toluene derivatives, 33
and undernutrition, amylolytic activity of pancreas, °107

HYPOTENSION, after glucagon, °457

HYPOTHALAMUS, and food intake, 357

HYPOTHYROIDISM, and carbutamide, 73

I

INSULIN
action
mechanisms, °123-124, 441
permeability hypothesis, 446-447, °464
and acute infections, 405
additives, °209
administration
in diabetic coma, ten rules, °295
and hepatic glucose-6-phosphatase activity, 27
after adrenalectomy, °296
alcohol disappearance rate after and after carbutamide, 32
amino acid composition, 234
and amphenone, 330-334
antagonists, 257

antibody technic for study in islets, 354-357
antiserum complex, 404
and β-cells, 224-227, 339-340
antibody, 402-405
and therapy duration, 406
and glucose tolerance tests, 406-407
granule content versus pancreas, 224
by serum globulins, 402
concentration
after centrifugation of fish islets, 338-340
in pancreas, 12-16
species difference, 32
degradation, 20, 54-59, 91
and Arbutin, 25
by liver, 58, °212
sparing action of hypoglycemic compounds, 271
in diabetes control, 46-53, 63-65, 175, °212, °460, °464
and arteriosclerosis, °544
changes, °542
cholesterol and serum lipoproteins, 347-352
evolution of modified, °123
and metabolism, °205
in pregnancy, 526, 531
selection for, and age, 328
requirements, °123, °125, °152, °208, °212, 278, 283, 406, 440, °456, °461, °464, °543
and unesterified fatty acids, 476-478
and dietary intake, °460, °542
dosage, 63-65, °464, 526
and uropepsin excretion, 481-483
and driving, °377
edema, °375
endogenous, species differences, 505-506
and glucagon, 249, 253-254
secretion, 256-257
structures, 238
and glucose, 89
functioning activity after, 245
in rat diaphragm, °118, °119
and glucose-6-phosphatase activity, °211
concentration in diabetic liver, 175
and glycogen in rat diaphragm, °380
and growth hormone, °298, 518-519
in perfused rat heart, °456-457
humoral antagonism associated with diabetic acidosis, °110-111
hypoglycemia
after adrenalectomy, °112
delayed convulsion-effect, °121
and adrenaline excretion, °116
and body metabolism in pig, °459
cerebral acetylcholine content during, °109
convulsion after, 278
neuronopathy, °382
portal route, 411
inactivation system, °119, °124, °212
inhibition, 30-31
of hepatic glycogenolysis, 34
intrapancreatic infusion, 77
in islets of Langerhans
isolation from tissue, 224
and zinc, 335-340
Lente, °297, °300, °545-546
Lente Iletin, protamine, zinc and nonprotein nitrogen comparative study, °462
lipodystrophy, and Gowers' local panatrophy, °545
metabolism, °124-125
compounds inhibiting degradation, 25-26
of radioiodinated, °300, 402
in obese-hyperglycemic mice, °466
oral substitutes, 259-261
and Orinase: *See* Orinase
after pancreas removal, 45, 147
and 2254 RP, 411
peripheral uptake, 424
in Cushing's syndrome, °458
potentiation
defined, 85-86
in depancreatized animals, 267
and protein metabolism, 514
reaction, 88
and blood sugar levels, °542
resistance
and ACTH, °114, °378-379
and diabetic acidosis, 407
immune antibodies as cause, 405
and Nadisan, °207
after somatotrophin and cortisone, °549
secretion, 11-12, °125, 265-267
and Prolactin, °111
sensitivity
adrenal role, 19, 440
and ascorbic acid pretreatment, °296
and cortisone, °549
and hydrocortisone, °206-207
and Orinase, 34-39
and pantothenic acid deficiency, °296
and removal of α-cell system, °295
and requirements, 257
return in diabetic coma, °211
and somatotrophin, °549
separation of guinea pig, chromatographic, °542
shock therapy in schizophrenia, 405
species specificity, 406
storage, 226
quantitative identification methods, 233
and zinc complexes, 339-340
and sulfonamides: *See* Sulfonamides
and sulfonylureas: *See* Sulfonylureas
synthesis
block of as cause of diabetes, 225
steps involved, 225
and tolbutamide, 77, 282-283, °547
comparison of effects on infused pentoses, 422-424
and 2254 RP, 411
zinc suspensions, °123, °296, °300

INSULINASE
and oral hypoglycemic compounds, 271
and Orinase, 16-18
role of, °212, 448
specificity of action, 32
and sulfonamides, 411
and sulfonylureas, 264-267

INTERCAPILLARY GLOMERULOSCLEROSIS: *See* Kimmelstiel-Wilson syndrome

INTERNATIONAL DIABETES FEDERATION, Third Congress, 303, 389, 471, 557

IPTD. *See* p-Aminobenzolsulfonamidisopropylthiodiazol

J

JAUNDICE
and carbutamide therapy, 43-45, 73, 76, 85
and sulfonamide usage, 43-44

K

α-KETOGLUTARATE
blood content, °540
in ambulatory diabetics, °299-300
and insulin, and Orinase, 42
and 11-17 oxygenated adrenal steroids, °543

KETONE BODIES
blood, and sulfonylurea therapy, 66
formation, in vitro
by liver slices, °109
metabolism, and ascorbic acid, °109
in urine
in brittle diabetes, °465
and unesterified fatty acid concentration after insulin, 477-478

KETONEMIA, bedside test, °457

KETONURIA, after insulin withdrawal, °210-211
in diabetes with acromegaly, 72

KETOSIS
diabetic
and fructose, °107-108, °546
and plasma nonesterified fatty acids, 476
prevention and treatment, °383
physiologic aspects of, °206
and response to hypoglycemic sulfonylureas, 286
and unesterified fatty acid metabolism in diabetes, 478
and withdrawal of insulin, °208

KIDNEY
autopsy findings, 69, 185, 430-431, 439-440
and carbutamide therapy, 6-7, 69, 73
damage, after Synthalin, 138
in diabetes, °212
acidosis, °114
and Addison's disease, 439-440
nephropathy, °457
pathologic findings, °294
thrombosis, coexisting, °548
and vascular lesion, °378, °547
failure
and diabetic coma, °296-297
in Kimmelstiel-Wilson type of glomerular damage, °459
function, °457, °459
and niacin excretion, 514
glomerulosclerosis, in diabetic and nondiabetic, 183
tubular reabsorption of acetoacetate, °109

KIMMELSTIEL-WILSON SYNDROME
See also Glomerulosclerosis
cholesterol, °548
and serum lipid fractions, 344-345, 351-352
and edema, °548
etiology and nature of, 488-495
lesions
like, after steroid therapy, 182
sites and types, 185, 488-495
specific for diabetes, °546
manifestations, °548

L

LACTATE
accumulation in Cushing's syndrome, °543
blood, and hydrocortisone, °206-207
differential permeability of rabbit placenta, °458

LENTE ILETIN, protamine, zinc and nonprotein nitrogen insulin comparative study, °462

LENTE INSULIN, 297, 300, °545-546

LIPID
in Kimmelstiel-Wilson syndrome, °548
metabolism, and atherosclerosis, 180-181
plasma and liver fractions and cortisone and/or epinephrine, °110
production and excretion, °108
saponifiable, fecal excretion, °461
serum levels, and hypercholesteremias, °466

LIPOPROTEINS
cholesterolemic rabbit, °122
serum fractions
and age, 344-345
β, in pregnant diabetic, 317-319, 322
and cholesterol determinations in diabetes, 342-352
and race, by sex, 344-345
species difference for radioactivity distribution, °379

LIVER
autopsy findings, 69
and carbutamide, 6-7, 14-16, 20, 24, 61, 73, °460
cirrhosis after, 44-45, 69
cholesterol, °108, °120, °378
damage, after Synthalin, 138-139
epinephrine effects on slices, 16-18
fatty, 6-7, °460, °466
after ethanol, °116-117
glucose, °466
and arylsulfonylureas, 33
in depancreatized dog during postabsorption, 38
and Orinase, 18
and sulfonylureas, 265
utilization, and previous diet, °125
glucose-6-phosphatase activity, °462
and carbutamide, 22-24
and sulfonylurea compounds, 91
glycogen, 14-16
degradation by β-amylase, 394
and glucagon intake, 255
molecular weight, 397-399
and Orinase, 34-39, 278
and sulfonamides, °459
and sulfonylurea compounds, 31, 91
and tolbutamide, 271-272
and venous glucose, 244
insulin-inactivating system, °119, °124, °212
intracellular distribution, °119
lipid fractions after cortisone and/or epinephrine, °110
and Orinase, 16-18, 34-39
perfusion through the isolated, °108, °378
lipolytic activity, °123
phospholipid turnover, °110
phosphorylase, 37, °124
enzymatic inactivation, °120-121
removal
and pancreatic circulation, 277
and responses to sulfonylureas, 270-271
site of hypoglycemic effects of arylsulfonylureas, 39
sulfonylurea effects, 31, 33, 37, 91
tissue, and N-Sulfanilyl-N′-butyl-urea, and N-(4-Methyl-benzolsulfonyl)-N′-butyl-urea, 26-27
viral hepatitis, °210

LUNG, after carbutamide therapy, 69-70

M

MALNUTRITION: *See* Nutrition

METHIONINE, and insulin synthesis, 225

MICROSCOPY, electron, of islets of Langerhans, 498-507

MÖNCKEBERG'S SCLEROSIS, in diabetic and nondiabetic, 183

MUCOPOLYSACCHARIDES, serum estimations, 186

MUSCLE
distal atrophy and paresthesias, °382
glucose and galactose transport into and insulin, °119
glycogen
after carbutamide, 14-16
comparison with in liver, 394-399
control by adrenal medulla, °456
by insulin, °120
molecular weight, 397-399
perivascular, after injection of insulin, °545

MYOCARDIUM
carbutamide effects, 68-70, 73
fibrosis, 161
infarction
autopsy findings, °384
and diabetes, 159, 164, 346, °464
transaminase activity, °115
metabolism in diabetes, 95-96
perivascular inflammation, 68-69

N

NADISAN, blood sugar reducing effects, 140, °207

NECROSIS
of liver, 6-7
pancreatic
in cortisone-treated children, °455
in Still's disease, °462
pituitary, in diabetics, °295

NEPHRECTOMY, and hypoglycemic response to tolbutamide, 270

NEPHRITIS, and diabetic pregnancy, °383

NEPHROPATHY, diabetic, 161, 165, 185
albuminuria as evidence, 161
and C 19-11 oxysteroids excretion, °548
eyeground changes, 163
and renal function, °457

NEPHROSIS
cholesterol and lipid intestinal excretion, °108
glomerular lesions, °544

NEUROMUSCULAR DISEASE, and pentosuria, °300

NEUROPATHY, and diabetes, 185, °209, °212, °378

NEUTROPENIA
and arylsulfonylureas, 61
and carbutamide, 69

NIACIN
excretion, and renal function, 514
metabolism, in diabetes, with complications, 510-512

NITROGEN
balance, 47-48, 50, 52
and glucagon dosage, 253-254
and growth hormone, 515
and testosterone, 269, 417
concentration, after centrifugation of fish islets, 338
metabolism, 150
and amino acid levels, 323
urea
excretion in adrenalectomized and glucagon dosage, 251
and glucagon dosage, 249-254
and growth hormone in pituitary dwarfism, 518
and hydrocortisone, °206-207

N-(4-METHYL-BENZOLSULFONYL)-N′BUTYLUREA, 26-27

N-SULFANILYL-N_2-N-BUTYLCARBAMIDE. *See* Carbutamide

N-SULFANILYL-N′-BUTYL-UREA, and liver tissue, 26-27

NUTRITION
amino acid preparations, 255
and amylolytic activity of pancreas, °107
carbohydrate, 2-7
and arylsulfonylureas, 61
and vitamin B complex, 279
feeding behavior, 233
hypothalamic control of food intake, 357
and lipophile dystrophy, 445
sorbitol as sweetening agent, °299
and tuberculosis in diabetic, 440
"why do animals eat?" 273

O

OBESITY
and average body weight, 289
definition, °110
and diabetes
cholesterol and serum lipoproteins, 349
preludin, °548
and sulfonylureas, 44, 63, 65
and glucose tolerance, °375
and unesterified fatty acids, 477
hyperglycemia syndrome, °117, 256
and overeating, 273
three forms, and glucose absorption, °117

ORINASE
See also Sulfonylureas; Tolbutamide
action, mechanism, 16-18, 53-54, 264-265, 274-276

after pancreatectomy, 34-38, 146-149, 277-278, 280-282, 289
and adrenocorticotropinase, 55, 58-59
and albumin serum content, 149
bilirubin response, 149
and blood sugar, 57, 59, 140-142, 280-282
arteriovenous differences, 34-36, 38
duration of effect, 88
after hypophysectomy, 10-12
bromsulphalein clearance after, 148-149
and carbohydrate utilization, 85-86
and carbutamide effects after alloxanization, 89
goitrogenic effects, 23
insulinase inhibitory activity, 16-18
in diabetes
adult obese, °108
alloxan, 141-142
and duration of illness, 283-284
of elderly, °108, °109
and etiology, 77-79
juvenile, °108, °109
metahypophyseal, 141
nonketonuric, 65
stable, 77
unstable, 65
and epinephrine, 16-18, 32, 37
and glucagon
glycogenolytic response to test, 254-255
in hepatic venous glycemia, 37
inhibition, 32
like effect on liver slices, 17-19
metabolism, 54-59
sensitivity of body, 34-39
and glucose
gut absorption, 141
plasma, radioactivity disappearance, 276
goitrogenic effect, 23
hypoglycemic responses, 37, °109, 141-142, °456, °461
and insulin
β-cell mitoses, °380-381
duration and effects, 89
insufficiency, 37
like action, 264
metabolism, 57-59
in peripheral utilization of glucose, 37-38
requirements, for infections, °456
sensitivity, 38
in islets of Langerhans, 141
β-cells, 53, °380-381
in ketoacidosis after hyperketonemia, 43
and liver
adrenocorticotropinase activity, 58
glucagonase activity, 58
glycogenolysis, 36
homogenates, 53-54
insulinase inhibition, 16-18, 58-59
in pancreas, 53, 380-381
and pantothenic acid serum levels, 514
pyruvate levels after, 44
time factor in effects of, 20

OVARIES, of newborn, luteinized follicular cysts, °455

OXALACETIC ACID, and zinc-insulin complexes, 339-340

P

PALMITIC ACID, oxidation, °124

P-AMINOBENZOIC ACID, ratio of acetylated to total in diabetic, °547

PANATROPHY, °545

PANCREAS
in Addison's disease with diabetes, 439
amylolytic activity, °107
in arteriosclerosis, °117-118
autopsy findings, 439
and carbutamide, 69-70
after steroids, in cat, 430
circulation
in absence of liver, 277
and sulfonylureas, 60
of cortisone-treated rabbits, °294, °456
enzymes, after amino acid additions to diet, °381-382
and glucagon secretion, 249, °466
insulin
content, 12-16, 19
secretion, 111, 226-227
islets of Langerhans
capillaries, 502, 504-505
and carbutamide, 41, °295-296, °459, °460
cell types, 222-229
α-atrophy production, 228
carbutamide effects, 41, 140-141
cobaltous chloride, differences in effects, 136
cytotoxins, 135-143
D-860 effects, 142
and decamethylendiguanidin, 137-138
degranulation, 232
and diethyldithiocarbamate, 135-136, 154-158
electron microscopy, 501-505
as glucagon source, 227-229, 232
and IPTD, 140, 232
and nickelous chloride, 136
ratio to beta in alloxan diabetes, °295
and sulfonylureas, 91, 232, 264
β-absence, diabetes cause, 225
antidiabetogenic hormone site, 224
carbutamide effects, 3, 6, 40-41
compensation by, °112
and D-860, 142
degranulation, 3, 6, 53, 232, 249
electron microscopy, 498-501, 505-506
hydropic degeneration, procedures for, 431
and insulin, 12, 224-227, 339-340
and IPTD, 263
mitoses after Orinase, °380-381
regeneration, 233, 413
and sulfonylureas, 91, 267
and thiodiazoles, 2254 RP and 2259 RP, 410-415
C, electron microscopy, 502
staining, 222
D, or ductular, 232-233
△ presence, species differences, 229
changes with age and hibernation, °382
cortisone responses, 232
electron microscopic features
cell differences, 505, 506
species differences in cell structure, 501, 505
endothelial cytoplasm, 506
excitation of insulin secretion by humoral pathway, 409
of fish, 338, 340
fluorescent antibody technic for insulin demonstration, 354-357
hyalinization
and carbutamide, 69
pathogenesis, °117-118
metabolism
histidin and zinc complexes, 339-340
insulin and zinc interactions, 335-340
necrosis and renal insufficiency, °459
nerve fibers, 505, 506
and Synthalin, 139, 228
and Prolactin, °111
and sulfonylureas, 31, 60, 91, 264
as site of action, 267
weight, and carbutamide, 21-23, 32

PANCREATECTOMY
and carbutamide effects, 45, °119, °123, °146-149, °294
toxicity, 151-153
and glucose excretion, °211
and hypoglycemic sulfonamides, 409
and insulin sensitivity, 37
and Orinase effects, 37, 146-149
subtotal, and hydropic degeneration of β cells, 431
and sulfonylureas responses, 8-9
and tolbutamide, 9, 78-79

PANCREATITIS
caused by fast and surfeit, °116
and diabetes, °466
genetic transmission, °542

PANHYPOPITUITARISM, and Nadisan, °207

PANTOTHENIC ACID and insulin sensitivity, °296
metabolism, in diabetes, with complications, 510-512
serum levels and Orinase, 514

PEMPHIGUS after cortisone therapy, 182

PENICILLIN
and hypersensitivity to carbutamide, 70
usage in diabetic, °295

PENTOSES, insulin and tolbutamide effects comparison, on infused, 422-424

PENTOSURIA, in neuromuscular disease, °300

PEPSINOGEN, blood levels, and glucagon, °541
excretion, and adrenocortical activity, 482-483

PETERS, John P., 99-103

PHLORIZIN, and reabsorptive rates of acetoacetate, °109

PHOSPHATE
balance, in diabetes, unstable, 50-53
renal tubular reabsorption, °109

PHOSPHOKINASE, inhibition, and Orinase, 17

PHOSPHOLIPIDS
plasma, in atherosclerosis, °122
turnover in plasma, liver, and aorta and cortisone and/or epinephrine, °110

PHOSPHORUS
balance, in diabetes, 47-48, 50, 52
organic compounds, and zinc-insulin complexes, 339-340
retention and growth hormone, 515
serum content and glucagon, 254

PHOSPHORYLASE, and glycogen, 393, 399

PITUITARY GLAND
ACTH
and hydrocortisone, °206-207
secretion, and chlorpromazine, 377-378
alkaline extract and growth, °110
growth hormone: *See* Growth hormone
and sulfonylurea compounds, 41, 92
tumors of, and reversible diabetes, °549
and uropepsin, urinary excretion, 482-483

PLACENTA
endarteritis, °540
permeability to sugars, °458

PLANTYM, °459

PLASMA
beta-lipoprotein levels and atherosclerotic lesions, 181
corticoid content and Nadisan, °207
glucagon disappearance rates in sulfonylurea-treated rabbits, 56
glucose after insulin and Orinase, 276
17-hydroxycorticosterone and carbutamide, °464
insulin, °380-381
electrophoretic patterns, 402-403
and pituitary growth hormone, °298
after sulfonylurea, 55
after therapy, °124-125
lipid fractions and cortisone and/or epinephrine, °110
phospholipids
in atheromatosis, °122
turnover, °110
phosphorus, and glucagon administration, 46-53
postheparin, fat emulsion clearance and in pancreatic lipase, °379

POLYNEURITIS, and diabetes, °544, °549

POLYSACCHARIDES, glycogen and cellulose, 391-392

POTASSIUM
balance, 51-53
in diabetic acidosis, °294
fluoride in blood sugar preservation, 176-178
renal tubular reabsorption of bicarbonate after, °111-112
retention and growth hormone, 515

PREDIABETES SYNDROME, °460

PREDNISOLONE
and glucose tolerance, 168-173
glycosuria and hyperglycemia after and Orinase, 281

PREDNISONE
and glucose tolerance, 168-173
and glycosuria in cats, 429

PREGNANCY, DIABETIC
abortion, therapeutic, 526-527
bacteriuria, 311
birth weights, °298, 327-329
blood pressure, 526
and pre-eclampsia, 528
blood sugar, 324-327
blood vessels, 307-322
changes and grading, 309-315
patterns, 318-322
relation to outcome, 320-322
responses of smaller, 363-364
carbohydrate metabolism and glucose tolerance, 324-329
and edema, 315
and family history of diabetes, 524
glucose tolerance test, °462-463, 524
trimester variation, 531-532
hormone therapy, 526, 530
incidence, 523-524
intermittent proteinuria, 311
intravascular erythrocyte aggregation, 310
labor induction, methods, 531
manifestations in latent, °545
mortality
fetal, °120, °299, °462-463, °541
infant, 524, °546
in pre-eclampsia, 528
perinatal, °462-463
and nephritis, °383
and number of pregnancies, °298
outcome, 320-322, 525-526
ovaries of newborn, °455
panel discussion, 523-533
pathological processes in the placentas, °540
and peripheral utilization of glucose, °375-376
prediabetic state, °457, °540
renal threshold for glucose, °382
serum protein responses, 317-319, 322, 363-364

PRELUDIN, for weight reduction in obese diabetics, °548

PROTAMINE, and thrombotic phenomena, °462

PROTEIN
intake
excessive, 353
and insulin reactions, °542
isolation, from pancreatic blood, °111
metabolism, 205
after hypophysectomy, 150
serum
in depancreatized dogs and carbutamide, or Orinase, 147-149
in diabetic pregnancy, 317-319, 322, 363-364

PROTEINURIA
and diabetic retinopathy, °114
intermittent, in pregnancy, 311
in Kimmelstiel-Wilson syndrome, °548

PTEROCARPUS MARSUPIUM, and renal threshold for sugar, °465

PYELONEPHRITIS, in Kimmelstiel-Wilson syndrome, °548

PYKNOSIS, cortisone induced zona fasciculata, °460

PYRUVATE
blood
after alcohol, and carbutamide, 28-29
in ambulatory diabetics, °299-300
in Cushing's syndrome, °543
and hydrocortisone, °206-207
in hyperadrenalinemia, 42
and insulin
hypoglycemia, 278
and Orinase, 41-42, 44
and sulfonylureas, 91
metabolism, by the newborn, °113-114
and 11-17 oxygenated adrenal steroids, °543

PYRUVIC ACID, blood level, after glucose, °122

PYURIA, in pregnancy, 311

R

RADIATION
lipoprotein concentration after species difference, °379

RASTINON
blood sugar reducing effect, 141
and insulin requirements, °458

RESERPINE, in schizophrenia, °455

RETINA
aneurysms, 182
in diabetics and nondiabetics, 183
diabetic changes, °210
hemorrhages, in hypertensive, 185
vascular changes, °378

RETINITIS
in childhood, °543
diabetes mellitus as cause, °459
grading of changes, 160-161

RETINOPATHY
appearance and development, °210
in Cushing's syndrome, 185
and diabetes mellitus, °212, °461, °548
cholesterol and serum lipoproteins, 346-348, 350-352
and duration of illness, °114
etiology and pathogenesis, °115
for general practitioner, °381
glucocorticoid excretion, 182
in Kimmelstiel-Wilson syndrome, 185, °548
and globulin levels, °547
hypertonicus fundus, °114
ophthalmic classification, °209
relation to neuropathy and nephropathy, 185
renal lesions with, 185
and vitamin B_{12} metabolism, 418-421, °456

RIBOFLAVIN, metabolism, in diabetes with complications, 510-512

RUBNER, Max, 369-371

S

SCHIZOPHRENIA
carbohydrate metabolism in after chlorpromazine or reserpine, °455
coma induction, and insulin retention, 405

SHOCK
hypoglycemic
after carbutamide in partially depancreatized dog, 41
and D-860, 141-142
after Synthalin A, 139
insulin, and insulin retention, 405

SKIN
in cat, after steroids, 430
rashes after carbutamide, 76, °125
and continuance of usage, 45

SOMATOTROPHIN, and insulin sensitivity, °549

SORBITOL, blood sugar responses, °299

SPLEEN, autopsy findings, sudden death, during carbutamide therapy, 69

STEROIDS
adrenal
and α-ketoglutaric acid, °543
blood level, and carbutamide, 86
and carbohydrate metabolism, 206-207
tolerance, °543
and epinephrine, °463
glucagon synergistic with, 254
peripheral effects, 41
and pyruvic acid levels, °543
and sympathetic nervous system, °463
and tolbutamide, 78-79
autopsy findings after, in cat, 430-431
dosage, and hyperglycemic responses, 174
glomerular lesions produced by, 182
and hypoglycemic sulfonamides, 409
stress due to lack, °463
and sulfonylureas, 41, 86, 92
therapy, °210
and insulin requirements, 406
and pancreatic necrosis, °455
urinary excretion, 46-53, 86
and Nadisan, °207

STEROLS, soya, absorption by the rat's intestine, °112-113

STILL'S DISEASE, pancreatic necrosis, °462

SUCCINIC ACID and ketosis in alloxan diabetes, °107-108

SUGAR
blood levels. *See* Blood, sugar levels
placental transfer mechanism, °458

SULFATE, renal tubular reabsorption, °109

SULFATHIAZOLE, sensitivity incidence, 73

SULFONAMIDES
See also Sulfonylureas
and adrenals, 43, 409
antidiabetic action of
2254 RP, 408-412, 414-445
2256 RP, 414
2259 RP, 413-415
bacteriostatic action, 415
and diabetic ulcerations, 414
and glycosuria, 414
and gonadectomy, 409
hypoglycemic effects, 47-52, 139-143, 149-153, °295, °300, 414
and antidiabetic, °301
and central nervous system, 409-410
and glucagon, 410
mechanism of action, 408-415
and insulin
sparing action, °114
substitute, 260-261
and jaundice, 43-44
and liver, glycogen content, °459
nonspecific inhibition of enzymes and blood lactate levels, 44
sensitivity incidence, 73
and thyroid function, 412
and thyroparathyroidectomy, 409

SULFONYLUREAS
adrenal responses, 41, 86
and agranulocytosis, 86
alphacytotoxic action, 232
autopsy findings after therapy, 89-90
Canadian and British experiences, 191-193
and diabetic complications, °458-459
dosage for antidiabetic effects versus toxicity, 288
field of usefulness, 92
and glucagon, 19, 31, 41, 54-59, 91, 275, 278, °540
and glucose
metabolism, 33, 34, 89, 267, 286
uptake, 27
and glucose-6-phosphatase, 26-27, 91, 275
in Houssay cats, 8, 10
and hyperglycemia after cortisone, 53
hypoglycemic action, 7-12, 41-43, 61, 91-92, °125, 267, 286, °384, °458-459, °540, °541
after adrenalectomy, 11-12, 53, 86, 91-92
of derivatives, °458-459
and duration of diabetes, 63-67
individual differences, 44
as insulin substitutes, 260-261, 278
mechanisms for, 53-54, 263-267, 274-277
oral compounds, 195
after pancreatectomy, 8-9
pluriglandular action, °460
versus toxicity, 103
after hypophysectomy, 10-11, 86, 91-92
and insulin
activity, 7-12, 85, °125, 277
blood pyruvate after, 91
destruction, 89, 91
inhibition, 30-31
like action, 264
metabolism, 20, 54-59
potentiation or secretion, 11-12, 265-267, °543
requirements, 63-67, 278, °543
sensitivity, 8-9
insulinase inhibition, 264, 271
intermittent usage and sensitivity reactions, 87
intrapancreatic infusions, 60
and liver, 31, 33, 37
glucose release and production, 264
glycogen levels, 31, 91
removal, 270-271
site for action, 39, 272
and nutrition, 61
and pancreas, 31, 60, 91, 232, 264
site for action, 267
pharmacologic limitations, 34
and thyroid hyperplasia, 92
toxicity, 64, 92
and dosage, duration of treatment, 86, 91
and white blood count, 86-87

SURGERY
in diabetic, management of procedures, °380
insulin requirements, and Orinase therapy, °456

SYMPATHETIC NERVOUS SYSTEM, and adrenal cortex, °463

SYMPOSIUM: Insulin, Glucagon and the Oral Hypoglycemic Sulfonylureas, 221-289

SYNTHALIN
See also Decamethylendiguanidin
as insulin substitute, 260
and liver injury, 289
mechanism of action, 263-264

T

TACHYCARDIA, and carbutamide, 73, 76-77

TES-TAPE, and urine glucose, 426-427

TESTOSTERONE
and growth hormone responses in pituitary dwarfism, 518
and nitrogen retention, 269
therapeutic use, 417

THIODIAZOLES
2254 RP, 408-412, 414-415
2256 RP, 414
2259 RP, 412-415

THROMBELASTOGRAPHY, thrombophilia in diabetes, 433-435

THROMBOCYTOPENIA, after carbutamide, 73, °208

THROMBOPHILIA, in diabetes, 433-435

THYMOL, in blood sugar preservation, 177-178

THYROIDECTOMY
and adrenocortical activity, °378
17-hydroxycorticosteroid metabolism after, °378

THYROID GLAND
and carbutamide, 6-7, 80-82, °108-109, °460
function, and sulfonamides, 412
hyperplasia after sulfonylurea therapy, 92

tumor, and reversible diabetes, *549
THYROPARATHYROIDECTOMY, and hypoglycemic sulfonamides, 409
THYROTOXICOSIS, cell size and thyroid hormone, 32
TOLBUTAMIDE
See also Orinase; Sulfonylureas
central and peripheral effects, 34-39
clinical use, 290-291
dosage and effects, 282-283
individual differences, 63-64, *458
species difference, 8-9
and glucose
release by liver, 271-272
transport, across cellular membranes, 36
hypoglycemic responses, 77-79, 270-272, 280-289, *377, *384
and sulfonamides, 9
and insulin
comparison of effects on infused pentoses, 422-424
requirements, 77, 282-283, *547
insulinase inhibition, 271
intrapancreatic infusions, 60
isopropyl, mechanism of action, 408-412
and pancreatic islet cells, *459
protein-bound iodine and conversion ratio decrease after, 61
response test for nonketonuric diabetes, 65-67
suggested dosage, *547
theories of mode of action, *547
toxicity, 283, 286-287, *541, *547
TOLUENE, responses to derivatives in hypophysectomized diabetic patient, 33
TOXEMIA OF PREGNANCY
and blood pressure, 311
nonspecificity of therapy, 528
and perinatal mortality, *462-463
TRANSAMINASE, myocardial infarction in experimental, *115
TRAUMA, insulin requirements in Orinase therapy, *456
TRICARBOXYLIC ACID CYCLE, in alloxan-diabetic livers, *111
TRICHLOROACETIC ACID, and glycogen molecular weight, 397-399
TRIIODOTHYRONINE, and growth hormone, responses in pituitary dwarfism, 518
TRYPSIN, glucagon hydrolysis, peptides from, 236-238
TUBERCULOSIS
of adrenal glands in Addison's disease with diabetes, 438, 440
and diabetes, *207, 440, *539-540
TURTLE, phrynops hilarii, diabetogenic action of growth hormone, *117

U

U-2043. *See* Tolbutamide
UREA, derivatives, structures, 408
URINARY TRACT, infections complicating diabetes, *301
URINE
excretions, after amphenone, 324-330
17-hydroxycorticoid excretion, 330-334
after arylsulfonylureas, 33
in diabetic retinopathy, 461
ketone bodies, in diabetic acidosis and unesterified fatty acids, 477
pepsinogen excretion in juvenile diabetes, 480-483
sugar content
after glucagon administration, 46-53, 253-254
carbutamide effects, 46-53, 70-72, 75
correlation with blood, *463
and dietary intake, 86, 249-251, 253-254
after growth hormone, 518-519
after hypoglycemic sulfonamides, 9
after Orinase, 281-282
postprandial, *462-463, *524
after sulfonylureas, 63
tests
Benedict, 297
Clinistix, *381
enzymatic, 358-361, *381
glucose oxidase, *114, *297, 426-427
simplified, *211
and unesterified fatty acid metabolism, 477
vitamin excretion
B_{12} in diabetic retinopathy, 418-421, *456
body stores and utilization ability factors, 511
UROPEPSIN, excretion in juvenile diabetes, 481-483

V

VALVULITIS, calcific in diabetes, 164
VASCULAR DISEASE. *See* Blood vessels, diseases
VEINS. *See* Blood vessels
VITAMINS
B, metabolism in diabetes, 508-512
B complex, in carbohydrate nutrition, 279
B_{12}
absorption impairment, 421
in diabetic retinopathy, *456
metabolism, 418-421
in diabetes with complications, 510-512
serum concentrations, 513-514
urinary excretion, and body stores or utilization ability, 511

W

WEIGHT
in alloxan diabetes, and hypoglycemic sulfonamides, 9
body
and bony skeleton, 179
and carbutamide, 3-6, 15, 24, 84
in diabetes, 47-48, 50-53
and dietary intake, 12-13
and glucagon dosage, 249-253
and obesity, 289
and sulfonamide therapy, 8-9, 414
and sulfonylurea therapy, 65
islets of Langerhans after carbutamide, 21-23
liver, and carbutamide, 24
molecular, of glycogen by different methods, 397-399
pancreas, and carbutamide, 32

X

XYLOSE, insulin and tolbutamide effects comparison, on infused, 422-424

Z

ZINC
in islet cells, 142, 156-157, 226
and insulin, 335-340
-suspension insulin: *See* Insulin, Lente

AUTHOR INDEX 1957

In this index are the names of the authors of articles which have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1957. Entries marked with an asterisk (*) indicate authors of material which appeared in the ABSTRACTS only. For subject index see page 1.

A

Abdala, Alberto, *294
Abramson, Daniel J., *455
Achelis, J. D., 40-41
Ackerman, R. F., *122
Ahlvin, Robert C., *455
Alella, A., *106
Alivisatos, John G., *106-107
Allegretti, Niksa, *205
Altschule, Mark D., *455
Alverson, Gabriele, *114
Anderson, George E., 34-40, 239-246
Anderson, Robert C., 2-6
Anderson, Walter L., *381
Andrews, C. T., *375
Ankenman, G. J., *455-456
Ashe, Benjamin I., *458
Ashmore, James, 26-27, *107
Ashworth, M. A., 21-23
Atkinson, R. M., *455

B

Baar, H. S., *455
Bacchus, Habeeb, *109
Bain, H. W., *109
Baird, Joyce D., *208
Baker, Herman, *456
Bakerman, Howard, 508-513
Balfour, John, *455-456
Barach, Joseph H., 342-353
Barbosa, Xavier, *547
Barrett, J. L., *107
Barrnett, Russell J., *117
Barta, L., *539
Bartlett, Marshall K., *116
Bastenie, Paul, *205, *375
Bastron, James A., *382
Bauer, Julius, *205
Bauer, Walter C., *455
Beardwood, Joseph T., Jr., *456
Beaser, Samuel B., *205
Beatty, Clarissa H., *107-108
Beaver, Elsye L., *125
Beck, Edith M., *547
Becker, W. H., *294
Behki, R. M., *462
Behrens, Otto K., *124, 234-238
Behrer, M. Remsen, *294
Bencosme, Sergio A., *294-295, *456
Bennett, Leslie L., *296
Berglund, Fredrik, *109
Beringer, A., *295
Berlinger, A., *295
Bernard, Jack A., *108
Berson, Solomon A., 54-60, 274-277, 402-405
Best, Charles H., *125, 151-153, *206, 248-252, *466
Betsch, William F., *213
Bhattacharya, S. K., *116
Bickel, J., *109
Bierman, Edwin L., 475-479
Bine, Réne, *378
Bloom, Arnold, *125
Bloom, Ben, *108
Bloom, Roy A., *375
Blumenthal, Herman T., *540
Bohan, Edward M., *539
Bolen, John G., *108
Bolene-Williams, C., *106
Bollman, Jesse L., *380
Bond, L., *119
Bonhôte, D., *207
Bookman, John J., *456
Bornstein, J., *119
Bose, S. N., *465
Boughton, C., *456
Bouman, J., *212
Bowen, Helen F., *120
Bowman, Roger H., *456
Bradley, R. F., 159-167
Brand, William, *205
Breneman, James C., *456
Brennan, C. F., *295
Brill, Gerald, *546
Brizzee, Kenneth R., *378
Brock, Benjamin L., *539-540
Broide, Lázaro, *295
Bromer, W. W., 234-238
Bronk, M. Sylvia, *456-457
Brown, Frederick, Jr., 64-67, *114
Bryfogle, J. W., 159-167
Bucht, H., *457
Buddecke, E., *294
Bunker, John P., *543
Burdon, J. F., *295
Burge, Dan, *375
Burkl, W., *295
Burns, Thomas W., *457, *540
Burstein, Robert, *540
Burt, Richard L., *375
Burton, Stanley D., *108
Buse, J. F., 7-12, 428-432
Butterfield, W. J. H., *540
Byers, Sanford O., *108, *111

C

Cahill, George F., Jr., 26-27, *540-541
Calvert, R. J., *540
Camerini-Davalos, Rafael, 74-77
Camp, J. L., *206, *540
Caplin, G., *540
Carleton, John L., *457
Carne, Stuart, *206
Carrington, Elsie R., *457-458, *540
Casares Escarra, Enrique, *298
Catteral, R. C. F., *298
Cavert, H. Mead, *376
Chaikoff, I. L., *112
Chambers, David C., *458
Chambers, R. A., *206
Charles, Bruce, *108-109
Charleson, Diana, *383
Chase, Lillian A., *109
Chow, Bacon F., 418-421
Chute, A. L., *109
Clancy, Carl F., *301
Clarke, W. T. W., *109
Clayton, S. G., *376
Cohen, Alan S., *458
Cohen, Ben, *458
Cohen, Julius J., *109
Colwell, Arthur R., *376
Colwell, Arthur R., Jr., 60
Colwell, John A., 60
Comfort, Mandred W., *542
Conn, Jerome W., 41-43, *206-207, *543
Conrad, V., *375
Constam, G. R., *207, *295-296
Cooper, David A., *207
Cooper, Donald W., *300-301
Costa, Erminio, *111
Coulson, Douglas, *213
Cox, Robert W., *124-125, 270-273
Coyne, Richard, *122, *299
Craig, James W., 77-79, 280-282
Creutzfeldt, Werner, 135-145, *207-208
Critchley, MacDonald, *545
Croom, J. Halliday, *376-377
Crowley, M. F., *125
Cullen, Richard C., *299, *465
Culver, Perry J., *116

D

Davidson, I. W. F., 248-252
Davidson, Joseph W., Jr., *384
Davies, Jack, 354-357, *458
Davies, M. C., *114-115
Davies, Mary H., *377
Debons, Albert F., *109
Delle Sedie, P. F., *109
Deluca, H. A., *379
Demanet, T. C., *375
de Meutter, R., *375
de Nicola, P., 433-435
Dickson, H. M., *109-110
Diengott, D., *114
Di Luzio, Nicholas R., *110
Ditzel, Jørn, 307-323
Dixon, F. J., *212
Dole, Vincent P., 475-479
Dolger, Henry, *456
Drury, Douglas, *377
Drury, M. I., *377
Duncan, Garfield G., 83-84, *208, *211
Duncan, L. J. P., *208, *208-209, *377
Dunlop, D. M., *208, *377
Dunn, M., *120
Durazo Quiróz, Francisco, *462
Dury, Abraham, *110, *296
Dury, Muriel, *296
Dworschak, W., *297-298

E

Earle, A. Scott, *540-541
Egdahl, Richard H., *377-378
Eik-Nes, Kristen, *378
Ek, J., *457
Elkan, B., 480-484
Elliott, K. A. C., *109
Ellis, Philip P., *543
Emerson, G. M., *110
Emerson, J. D., *110
Enderlin, Martin, *541
Engleson, Gunnar, *209
Erk, Vernon, 80-82
Est, Mladen, *205
Ettinger, Richard H., *466
Evans, Herbert M., 256-258

F

Fabrykant, Maximilian, *458
Fagerberg, Sven-Erik, *209
Fajans, Stefan S., 41-43, *206-207, *543
Farrell, Gordon L., *121
Federman, Daniel D., 67-72, 508-513
Feigenbaum, Lawrence Z., *108
Feinblatt, Theodore M., *209
Fellmann, H., *207
Felts, J. M., *112
Fenton, Paul F., *110, *375
Ferguson, Edgar A., Jr., *209
Field, James B., 67-72, *110-111, 508-513
Fink, Harold, 154-158
Fisher, George R., *213
Fisher, R. B., *456-457
Flinn, Lewis B., *541
Foà, Piero P., *111, *458-459
Fodden, John H., *111
Foley, J., 422-425
Forney, Robert B., 28-30
Forster, H. Walter, Jr., *209
Forsyth, Constance C., *296
Franckson, J. R. M., *375
Frank, Ludwig L., *541
Frawley, T. F., 422-425
Freedman, Lawrence R., *459
Frehner, H. U., *461-462
Friedenwald, Jonas S., *461
Friedman, Meyer, *108, *111, *378
Friskey, Roger, 64-67, *114
Froesch, E. Rudolf, 33, 515-522
Frohman, Charles E., *111
Fuller, B. F., *541
Fuller, George R., *111-112

G

Galansino, Giorgio, *111
Galin, Miles A., 154-158
Ganong, William F., 515-522
Gardell, S., *213
Gassmann, W., *378
Gastineau, Clifford F., *541
Gellis, Sydney S., *383
Ghanem, M. H., *210
Gibbs, Gordon, *378
Gifford, Edward S., Jr., *210
Gifford, H., *378
Giges, Burton, *466
Gillison, T. H., *378
Ginsburg, Jean, *112, *296
Gitelson, S., *378
Glicksman, Arvin S., *210, *379
Goicoechea y Quirós, Pilar, *298
Goldner, Martin G., 53-60, 259-262
Goldring, David, *294
Goldsmith, L., *542
Goldstein, Franz, *213
Goldstein, M. S., *463
Goncz, Rose-Marie, *455
Goodale, Walter, 515-522
Goodbody, R. A., *379
Goodwin, R. F. W., *459
Gordon, M. F., 7-12
Gordonoff, T., *459
Gottfried, J., *114
Graef, Irving, 196-197
Gray, C. H., *210
Grayzel, H. G., 480-484
Greben, Stanley E., *457
Grice, M. S., *120
Griffith, Isabelle, *548-549
Grindlay, John H., *380
Gross, John B., *542
Grossland, James, *109
Guerrero, Francisco G., *459
Gundersen, Kare, 428-432

H

Haar, Helmut, 80-82
Hackedorn, Howard M., *296
Hagen, H., *298-299
Hainline, Adrian, Jr., *114, *297
Haist, R. E., 21-23, *107
Hall, W. E., *112
Halmi, N. S., *549
Hardwick, C., *540
Harold, Franklin M., *112
Harris, Paul N., 2-6
Harrison, Joan, *119
Hartman, Alexis F., *294
Hartmann, H., *112
Hastings, A. Baird, 26-27, *107
Haunz, E. A., *542
Havens, W. Paul, Jr., *210
Hawkins, Rosemary D., 21-23
Hayes, Thomas L., *379
Hazlewood, Robert L., *296
Heale, T. A. F., *542
Heinivaara, Olli, *459
Heinsius, Ernst, *543
Heller, A., *207
Helps, E. P. W., *379
Henley, Elaine D., *124-125
Henn, Mary J., *378
Henneman, Dorothy H., *543
Hennes, Allen R., 41-43, *543
Hensler, L., *112
Hertz, Roy, 330-334
Hewitt, John E., *379
Hoar, Carl S., Jr., *540-541
Hoet, Joseph J., 330-334
Hollett, Charlotte, *379
Holliday, Phyllis D., *455
Holling, H. E., *540
Homan, J. D. H., *212
Hong, S. S., *381
Höpker, W., *543
Howard, Everett E., *380
Howick-Smith, C., *460
Hrubec, Zdenek, 342-353
Hsia, David Yi-Yung, *383
Hughes, Ann M., *383-384
Hulpieu, Harold, 28-30
Hunt, J. A., *210, *210-211
Hunter, R. B., *211
Hurt, J. E., 436-441
Hutchins, Merrill, 426-427

I

Ingle, Dwight J., *211
Introzzi, P., 433-435
Irving, R. E., *296-297
Ishida, Tadashi, *108, *378
Ivy, A. C., *112-113, *115-116, *460, *461
Izzo, Joseph L., 45-53

J

Jablokow, Victor, 426-427
Jackson, Raymond S., *458
Jackson, W. P. U., *297, *460
Janes, Ralph G., *543
Jenson, William K., *213
Jersild, M., *297
Joelson, Robert H., *456
Johnson, John A., *376
Johnson, L. H., *119
Johnston, Joseph A., *297
Joiner, C. L., 83-84, *380
Joos, Thad H., *297
Justiniani y Longa, Federico, *298

K

Kalant, N., *113
Kantor, Nathan, 176-179
Kappeler, R., *113
Kark, Robert M., *546
Karp, Dorothy, *383
Karvinen, Esko, *460, *461
Katz, L. N., *106
Kelson, M. J., *381
Kemp, James A., *460-461
Kemp, Robert L., *122, *299
Kerlan, Martin, *380
Kerlow Jinich, Aaron, *462
Kerppola, W., *547
Kilby, Ralph A., *123
Kim, K. S., *380, *461
Kimmelstiel, Paul, *543-544
Kimmelstiel, Ruth, *113-114
King, John W., *114, *297
Kinsell, Laurance W., 64-67, *114
Kirtley, W. R., 72-73
Kits van Heijningen, Adrienne J. M., *380
Kleeberg, J., *114
Klein, R., *297
Knepshield, Ann, 418-421
Knights, Edwin M., Jr., 426-427
Knowles, Harvey C., Jr., *114, 369-371
Knox, Kenneth R., *211
Kocen, R. S., *544
Kohn, J., *380, *544-545
Koletsky, Simon, *121
König, M. P., *211
Kornerup, Tore, *114
Kracht, Joachim, *380-381, *459-460
Krahl, M. E., 91-92
Kreiger, Ingeborg, *381
Kritchevsky, David, *114-115
Kritzer, Morton D., *122
Kröner, Barbara, *380-381, *459-460
Kuether, Carl A., 23-25
Kuhl, W. James, 61

L

Labhart, A., *207
Lacy, Paul E., 354-357, 498-507
Laken, Bertram, *547
Lambert, Edward H., *382

Lancaster, W. M., °545
Langdon, Robert G., °211
Laron, Z., °297
Lasch, H. G., °211
Laurell, S., °115
Lawrence, R. D., °210-211, °297
Lazarow, Arnold, 222-232
Lazarus, Sydney S., 53-54, °294-295, °456
Lee, Charles T., 83-84, °211, °380
Lee, Henry M., 23-25
Lee, Kyu Taik, °384
Leese, W. L. B., °300
Lehmann, Orla, °209
Leibel, B. S., °115
Lemley-Stone, Janet, °115
Lenzner, Alfred R., °461
Leonard, Edward, °115
Leonards, Jack R., °381
Lerman, Sidney, °115, °461
Levine, Rachmiel, 263-269
Levison, William, °545
Lewis, J. G., °461
Lewis, Paul L., 358-362
Lin, Tsung-Min, °112-113, °115-116, °460, °461
Lindner, A., °295
Little, J. A., °112
Loder, L. L., °381
Logan, John B., °114-115
Lotspeich, William D., °109
Loubatieres, Auguste, 408-417
Lowy, Alexander D., Jr., 342-353
Luft, R., °116
Lukens, Francis D. W., 7-12, 91-92, 358-362, 428-432
Luntz, George, °381
Lynch, Matthew J. G., 488-497

Mc

McCandless, R. F. J., °114-115
McConahey, William M., °381
McCullagh, E. Perry, °106-107, °116, °549
McDaniel, Ernest, 508-513
McDermott, William V., Jr., °116
MacDonald, Mary K., °116
McGavack, Thomas H., 80-82
McKendry, J. B. R., °461
McKenzie, J. M., °211
MacLeod, Martha B., °111-112
MacNeal, Perry S., °211-212

M

Macgregor, A. G., °377
Maengwyn-Davies, Gertrude D., °461
Magee, D. F., °381
Magee, Kenneth R., °545
Maier, C., °461-462
Malins, John, °545
Mallov, Samuel, °116-117
Malone, R. G. S., °295
Mann, George V., °465-466
Marble, Alexander, 74-77, °545-546
Marczynska-Robowska, Maria, °462
Marlette, Robert H., °380
Marques, Maria, °117
Marshall, P. B., °211
Martin, M. Mencer, °298
Martinez, Carlotta, 23-25
Maske, Helmut, °212, 335-341
Matthijsen, R., °212
Mayer, Jean, °117, °466
Meiklejohn, A. P., °377
Mendelow, Harvey, °546
Mendenhall, E. N., °120
Meneely, George R., °115
Meng, H. C., °379
Meranze, David R., °549
Merrill, Joseph M., °115
Metzler, W. S., °117
Michaels, George D., °114
Mikhail, Maurice, °210
Miller, Max, 77-79, 99-103, 280-282
Miller, Ruth, °119
Mirsky, I. Arthur, °212
Mohnike, G., °382
Moinat, Pierre, 307-323
Moloney, P. J., °542
Monaco, Robert N., 34-40, 239-246
Mookerjea, Sailen, °546
Moorhouse, John A., °546
Moran, John J., 358-362
Morgans, M. E., °300
Morita, Toshiko N., °118
Morrell, Roger Merritt, 485-487
Mosca, Leonardo, °382
Moschcowitz, Eli, °117-118
Moss, James M., °462
Moyer, A. W., °114-115
Mueller, H., °294
Mulder, Donald W., °382
Mulholland, Henry B., °546-547
Müller, F., °118
Muñiz Cano, Reinaldo, °298
Munk, K., °212
Munro, I. B., °297
Murdock, Thomas P., °547
Murison, Paul J., °382
Murray, D., °297
Murray, Ian, °212
Myers, W. P. Laird, °210

N

Nabarro, J. D. N., °208-209, °300
Nakada, Henry I., °118, °118-119
Narahara, Hiromichi T., °119, °300
Nath, M. C., °462
Navarro, Manuel D., °459
Nelson, Marjorie, °296
Nesbett, Frances B., °107
Nikkilä, E. A., °547
Nishikawara, M. T., °107
Nissel, W., °297-298
Nutley, Mary L., °300

O

Oakley, Wilfrid, °208, °209, °210-211, °298
Ogryzlo, M. A., °119
Olivere, Peter J., °539
Olney, Mary B., °382
Olson, O. Charles, °547
Oppé, T. E., °383
Oppenheimer, Henry E., °383
Orloff, Jack, °115
Orten, James M., °111
Osborn, R. A., °462
O'Sullivan, M. O., °112

P

Paley, Ronald G., °213, °300, °377
Pappius, Hanna M., °109
Pareira, M. D., °119
Park, C. R., °119
Parkhurst, Leonard W., °213
Parsons, B. J., °455
Patmalnieks, J., °213
Paton, A., °112, °296
Patrick, S. J., °462
Paullada, Juan José, °462
Paulson, Walter O., °298
Payne, W. W., °296
Peck, Franklin B., Sr., 1
Peden, J. C., Jr., °119
Pedersen, Jørgen, °120
Pedowitz, Paul, °462-463
Penington, J. S., °463
Pennock, L. Lewis, °547
Perfetto, A. John, 34-40, 239-246
Perisutti, Gladys, °212
Perkins, E., °456
Perry, W. F., °120
Peters, Edmund L., °300
Pettinga, C. W., 23-25
Pincus, I. J., °120
Pitts, Robert F., °111-112
Pogell, Burton M., °461
Pogorelskin, Milton A., °300
Portuondo do Castro, J. M., °298
Post, R. L., °119
Pratt, R. T. C., °206
Preiss, H., °301

Q

Quesada y Ramírez, Emilio de, °298

R

Rabin, Erwin R., °384
Rabson, S. M., °120
Rall, T. W., °120-121
Ralli, Elaine P., °547
Ramey, Estelle R., °463
Ramond, Félix, °463
Randle, P. J., °298
Raphael, Stanley S., °488-497
Rauschkolb, Elizabeth, °121
Rausch-Stroomann, J. G., °463-464
Rawson, Rulon W., °210, °379
Read, Willard O., °111
Reardon, Helen S., °457-458, °540
Reinhardt, David J., III, °213
Reinhold, John G., 358-362
Reisman, Martin, 154-158
Remein, Quentin R., 324-329
Renold, Albert E., 33, °107, 330-334, 515-522
Reynall, P. C., °298
Richards, John B., °377-378
Ricketts, Henry T., 62-64, 91-92
Rifkin, Harold, °548
Riley, J. S., °119
Rinzler, Seymour H., °383
Rippy, Edwin L., °383
Rob, C. G., °464
Robbers, Hans, °121
Robbins, Edward D., °108
Roberts, Sidney, °125
Roberts, Thomas N., 475-479
Robertson, James, °548
Robertson, S. E. J., °121
Robillard, Rosario, °548
Rogers, John, 211-212
Romine, Marjorie K., 508-513
Roncone, Angela, 45-53
Root, Howard F., 74-77
Root, Mary A., 12-16

Rosenman, Ray H., °108
Ross, E. J., °464
Rosten, B. M. D., °298
Rowell, N. R., °296-297
Rowen, Manuel J., °464
Rubin, Herbert B., °464
Rudolph, Irving, 154-158
Rutman, J. Z., °120

S

Sadhu, D. P., °546
St. George, Shirley, °111
Salter, J. M., 248-252
Satke-Eichler, Inge, °121
Sauer, H., °463-464
Schambye, Per, 146-150
Scheffler, H., °298-299
Schimpf, K., °211
Schmitt, George F., Jr., °464
Schneeweiss, J., °299, °378
Schuck, Janet, 508-513
Schulman, Jerome L., °457
Schulman, Martin P., °124
Schumacher, H., °121-122
Schumacher, J., °121-122
Schumaker, Verne Norman, °122
Scott, Earl G., 23-25
Scott, E. M., °548-549
Seegers, Winnifred, 80-82
Segal, S., 422-425
Selenkow, Herbert A., 515-522
Sepaha, G. C., °465
Serino, Girard S., °539
Shafer, Marion R., °383
Sheppard, Benjamin L., °465
Sheppe, William M., °465
Sheppe, William M., Jr., °465
Sheridan, E. Paul, °299, °465
Shlevin, Edmund L., °462-463
Shore, M. L., °122
Shrifter, Norman, °122
Shuffstall, Richard M., °299
Shull, Kenneth H., °465, °466
Shuman, Charles R., °122, °299, °457-458, °540
Siegel, Benjamin V., °383-384
Silvis, Capt. Richard S., °122-123
Simon, G., °539
Simon, Lt. Daniel S., °122-123
Sinn, L. G., 234-238
Sirek, Anna, °123, 151-153, °466
Sirek, Otakar V., °123, 151-153, °549
Skouby, Arne P., °384
Smelo, Leon S., 449-451
Smith, Beverly Chew, °299
Smith, D. H., °455
Smith, Forrest M., Jr., °300-301
Smith, G. W., °123
Smith, Kendrick A., °458
Smith, M. J. H., °299-300
Smout, M. S., °549
Sobel, Gerald W., 263-269
Soule, Samuel D., °540
Spalding, W. B., °123
Speck, Friedl, °121
Spencer, A. G., °300
Spitzer, John J., °123
Splitter, Thomas Stanford, 64-67
Spray, G. H., °298
Spirtos, B. N., °549
Spühler, O., °207
Stadie, William C., °123-124, 291-293
Stambul, Joseph, °549
Staub, A., °124, 234-238
Steinhardt, O., °295
Sternberg, A., 480-484
Stetten, DeWitt, Jr., °110-111, 391-401
Stewart, G. A., °125, °301
Stone, Howard H., 418-421, °461
Stowers, J. M., °211
Stumpf, Ch., °121
Suter, H., °459
Sutherland, Earl W., °120-121, °124

T

Talpers, Stanley J., 64-67
Taylor, K. W., °299-300
Tepperman, Jay, °124
Termine, Charles M., 34-40, 239-246
Tesar, W. C., °114-115
Thomas, Wilbur A., °384
Thorn, George W., 33, 330-334, 515-522
Thornton, W. Norman, Jr., °546-547
Thorogood, D. E., °210
Toll, William G., °456
Tomizawa, Henry H., °119, °124, °300
Törnblom, Nils, °300
Tourtellotte, Charles R., °466
Tower, Donald B., °300
Travell, Janet, °383
Tulloch, J. A., °462
Tunbridge, R. E., °213, °300
Tyler, Russell D., °466

U

Underdahl, Laurentius O., °541
Unger, Roger H., °384
Uraic, Durda, °205

V

Vander Veer, Joseph B., °213
Vaughan, Martha, 16-18
Villee, Claude A., °113-114
Volk, Bruno W., 53-54, 54-60
von Euler, U. S., °116
von Glahn, William C., °459
v. Holt, Clause, °380-381, °459-460
v. Holt, Linde, °380-381, °459-460
von Rechenberg, H. K., °121

W

Wajchenberg, Bernardo L., 41-43, °543
Waldron, Jerome M., °213
Waldstein, Sheldon S., °466
Walker, G., °300
Walker, Joan B., °300, °384
Wallace, John W., °109
Wang, Ian, °212
Warshall, H. B., 480-484
Watson, E. M., °549
Watt, J. G., °124
Watt, Philip, °458
Weakley, David R., °211
Weaver, J. A., °295
Webster, B. H., 436-441
Wedgwood, J., °549
Weisenfeld, Shirley, 53-54, 54-60
Weiss, Murray J., °464
Weissberg, William W., °464
Welsh, George W., °124-125
Wenger, V., °207
Werkö, L., °457
West, Edward S., °107-108
West, Kelly M., 168-174
Whitney, John E., °125
Wick, Arne N., °118-119, °377
Wildberger, Henry L., 62-64
Wilkerson, Hugh L. C., 176-179, 324-329
Williams, F. L., °106
Williams, Robert H., 25-26, °119, °124-125, 270-273, °300
Winegrad, A. I., 33
Wirts, C. Wilmer, °300-301
Wislicki, L., °378-379
Wohl, Michael G., °122, °299
Wolf, H. J., °301
Wolff, Frederick W., °125, °208-209, °301
Wolff, O. H., °455
Woodson, Minnie L., 508-513
Woolf, N., °297, °460
Worm, M., °382
Worth, Harold M., 2-6
Wosilait, Walter D., °120-121, °124
Wrenshall, G. A., °125
Wyman, A. L., °301

Y

Yalow, Rosalyn, 54-60, 274-277, 402-405
Yannoni, Claudine Z., °117
Young, F. G., °298, °301
Young, Keith R., °301

Z

Zahler, F. Marshall, °301
Zighera, Claudine F., °117
Zilversmit, D. B., °122
Zimmermann, Ole Christian, 537

Book Reviewers

Frank N. Allan, M.D., Boston
Benjamin I. Ashe, M.D., New York
Charles H. Best, M.D., Toronto
Edward L. Bortz, M.D., Philadelphia
Romeo Boucher, M.D.,* Montreal
A. Lawrence Chute, M.D., Toronto
Arthur R. Colwell, Sr., M.D., Chicago
Jerome W. Conn, M.D., Ann Arbor
T. S. Danowski, M.D., Pittsburgh
Norman Deane, M.D., New York
Garfield G. Duncan, M.D., Philadelphia
W. Wallace Dyer, M.D., Bryn Mawr, Pennsylvania
Peter H. Forsham, M.D., San Francisco
Jonas S. Friedenwald, M.D.,† Baltimore
Elmer S. Gais, M.D., New York
Irving A. Glass, M.D., New York
Martin G. Goldner, M.D., New York
George M. Guest, M.D., Cincinnati
Reed Harwood, M.D., Boston
Blair Holcomb, M.D., Portland, Oregon
Robert L. Jackson, M.D., Columbia, Missouri
Henry J. John, M.D., Cleveland
Harvey C. Knowles, Jr., M.D., Cincinnati
Abbie I. Knowlton, M.D., New York
Alexander Marble, M.D., Boston
Helen S. Mitchell, Dean, Amherst, Massachusetts
Rosemary Murphy, M.D., Boston
Lester J. Palmer, M.D., Seattle
Kermit L. Pines, M.D., New York
Herbert H. Pollack, M.D., New York
Henry T. Ricketts, M.D., Chicago
Howard F. Root, M.D., Boston
George Schmitt, M.D., Miami
J. W. Scott, M.D., Toronto
Penn G. Skillern, M.D., Cleveland
Randall G. Sprague, M.D., Rochester, Minnesota
William C. Stadie, M.D., Philadelphia
Sidney Weinhouse, Ph.D., Philadelphia
Abraham White, M.D., New York
Russell M. Wilder, M.D., Rochester, Minnesota
Wallace M. Yater, M.D., Washington, D.C.

*Guest book reviewer, 1955.
†Deceased.

Members of the Association and subscribers to DIABETES may secure an additional metal rod without cost, for the purpose of inserting this Index in their volume binders. Address your request to the American Diabetes Association, Inc., 1 East 45th St., New York 17, N. Y.

American Diabetes Association, Inc.
1 East 45th St.
New York 17, N. Y.